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Chapter 1
Chapter I: General Introduction 
1.1 The Genetic Basis of Hereditary Cancer
Cancer has long been recognized as a multifactorial disease, the result of a combination of 
the genetic constitution of an individual, somatic mutations and environmental factors of a 
single cell. The process of oncogenesis can be defined as the somatic accumulation of 
mutations affecting a limited number of genes, i.e. genes involved in either positive 
(oncogenes) or negative (tumor suppressor genes) stimulation of cell growth and 
differentiation, in a clone of cells over time. This describes the evolutionary nature of tumor 
development. The initial hit predisposes a cell to cancer but additional mutations are 
necessary to initiate cancerous outgrowth.
The search for and the identification of the genes/proteins involved in this multi-step 
process have provided important insights into the pathogenesis of both inherited and sporadic 
cancer. The majority of the necessary genetic mutations can only be found in the individual’s 
cancer cells but ~1% of all cancers arise in individuals affected by a hereditary cancer 
syndrome. These patients are carriers of a genetic mutation present in all cells of their body. 
Inherited genetic susceptibility to cancer usually shows Mendelian dominant inheritance with 
a high, although often incomplete, penetrance and the cancer appears at earlier age. A “loss of 
function” mutation present in one copy of a recessive cancer gene predisposes these carriers 
to a specific cancer or cancer types. This principle has provided the way to identify the genes 
involved in Mendelian cancer syndromes.
A few cancer syndromes have been attributed to activating mutations in dominant cancer 
genes, such as multiple endocrine neoplasia type 2 [1], hereditary papillary renal cancer [2], 
and familial melanoma [3] which are caused by mutations in the RET gene, the MET gene and 
the CDK4 gene, respectively. A second hit in the remaining normal allele of these genes is not 
necessary since the inherited “gain-of-function” mutation behaves dominantly in the cell. 
However, somatic mutations in other genes are still needed for cancer development.
The third distinct group of hereditary cancer syndromes results from mutations in genes 
ensuring the integrity of the genetic information. These so-called mutator genes have to 
sustain “loss-of-function” mutations in both copies, which results in defective replication or 
DNA-repair. This raises the mutation rate and predisposes the carrier to cancer, as has been 
shown in hereditary non-polyposis colon cancer (HNPCC) [4].
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Mutational events that affect any of these genes, i.e. tumor suppressor genes, oncogenes, 
and mutator genes, either increase the population of predisposed tumor prone cells or affect 
the genomic stability of the cell. Both effects enhance the evolutionary nature of cancer 
making successive mutations more likely. In the next sections I will discuss in greater detail 
some of the genes involved and the strategies used to identify them.
1.2 Oncogenes
Normal cellular genes involved in the positive regulation of cell proliferation are termed 
“proto-oncogenes”. The altered gene copy is called “oncogene” if a dominant activating 
mutation is present. The concept of the oncogene originated from the discovery that certain 
genetic elements in retroviruses were capable of transformation [5]. It became apparent that 
these dominant transforming viral genes (v-onc) were actually altered forms of normal 
cellular counterparts (c-onc) [6, 7] and that these genes were commonly mutated/activated in 
human cancers.
Several basic genetic alterations can convert a proto-oncogene into an oncogene. The 
activating mutation might be a point mutation, a deletion, an insertion, an amplification, or a 
chromosomal translocation. All these mutations give rise to a hyperactivity or overexpression 
of the protein product. The activating mutations are almost invariably somatic events; they are 
dominant and normally affect only one copy of the gene. A classic example of an activating 
chromosomal translocation is the chronic myeloid leukemia associated Philadelphia 
translocation, first described in 1960. Two chromosomal regions, 9q34 containing the ABL 
gene that encodes a membrane associated tyrosine kinase, and the breakpoint cluster region 
(BCR) on chromosome 22, recombine and form a hybrid gene. This gene encodes an aberrant 
ABL protein with increased tyrosine kinase activity [8-10].
Another activating process often detected in tumors and tumor cell lines is the 
amplification of specific chromosomal regions. These regions contain multiple copies of 
normal proto-oncogenes resulting in a greatly increased gene expression. The MYC gene was 
the first proto-oncogene shown to be amplified, both in a promyelocytic leukemia cell line 
and the corresponding primary tumor [11, 12]. Oncogene amplification has been 
demonstrated in several other tumor cell lines and tumors since. For example, in small cell 
lung carcinomas members of the MYC oncogene family are frequently present in multiple 
copies [13, 14]. Another gene often amplified is the ERBB2 gene, particularly in mammary 
carcinomas of a more advanced stage [15].
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Only a few oncogenes have been associated with germline mutations in hereditary cancer 
syndromes. The RET gene was the first proto-oncogene implicated in hereditary cancer, 
namely in multiple endocrine neoplasia type II (MEN2). Germline mutations at specific 
cysteine residues were identified that produce a constitutive activation of this cell-surface 
tyrosine kinase receptor [1, 16]. Hereditary papillary renal carcinoma (HPRC) has been linked 
to similar “gain-of-function” germline mutations in the tyrosine kinase domain of the MET 
oncogene [2]. The cyclin dependent kinase CDK4 (a Thr/Ser kinase) was shown to be 
mutated, although at low frequencies, in familial melanoma [3]. The detected germline 
mutation was located in the p 16-binding domain of CDK4 creating an oncogenic protein 
resistant to normal inhibition by the tumor suppressor p16. Recently, another member of the 
transmembrane tyrosine kinase receptor family, the KIT oncogene, was shown to be mutated 
in a familial case of gastrointestinal stromal tumors (GIST)[17].
1.3 Tumor suppressor genes
Cell fusion experiments provided functional evidence for the existence of tumor suppressor 
genes. When malignant cells were fused with benign cells the malignancy could be averted 
[18]. Tumor suppressor genes are defined by the loss (absence) of the protein (activity) in 
cancer cells. Already in 1971 Knudson developed his “two-hit” theory, a general mutational 
model for tumor suppressor genes, to explain properties of retinoblastoma [19]. He suggested 
that one normal allele of such a gene would be enough to protect against oncogenesis. Thus, 
two inactivating mutations are needed in the hereditary cancers: one germline and one somatic 
mutation. The first evidence for such a “two-hit” model was provided by the identification of 
a consistent deletion on the long arm of chromosome 13 in retinoblastoma tumors [20]. 
Further support for the “two-hit” hypothesis came from family studies, showing involvement 
of the same chromosomal region in familial retinoblastoma [21]. It was not until 1986 that 
this “two-hit” hypothesis was shown to be correct with the identification of the retinoblastoma 
or RBI gene through positional cloning strategies [22-24]. Cancer cells were shown to carry 
two independent mutations in the RBI gene and patients with an inherited predisposition to 
develop retinoblastoma carried a mutant RBI allele that could be detected in all tissues [25]. 
Furthermore, transfection experiments with the wild-type RBI gene using retinoblastoma, 
osteosarcoma, and prostate carcinoma cells provided evidence of the tumor suppressive 
capacity of RBI [26, 27].
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The loss of DNA at specific chromosomal regions, recognized by cytogenetic analysis or 
loss of heterozygosity (LOH) at a polymorphic site, became an important pointer in the 
identification of regions that contain tumor suppressor genes and the experimental sequence 
mentioned above has served as a “standard” approach to identify tumor suppressor genes. 
Over the years an impressive number of hereditary cancer syndromes has been attributed to 
germline mutations in specific genes (table 1). Unraveling the function of the identified tumor 
suppressor genes turned out to be much more difficult. Two important tumor suppressor 
genes, RBI and p53, will be discussed below. Their products regulate two main cell cycle 
regulatory pathways often affected in cancer cells
Table 1: Tumor suppressor genes and human cancer syndromes. Germline mutations of these 
genes have been identified and predisposes to human cancer.
Tumor Human gene identified
suppressor chromosomal function cancer syndrome
gene location
RB1 13q14 cell cycle, transcriptional regulation Familial retinoblastoma
Wt1 11p13 transcriptional regulator Wilms tumor
p53 17q11 transcription factor / response to DNA damage 
and stress / apoptosis
Li-Fraumeni syndrome
NF1 17q11 Ras-Gap activity Von Recklinghausen neurofibromatosis
NF2 22q12 ERM protein / cytoskeletal regulator Neurofibromatosis type 2
VHL 3p25 regulates proteolysis / elongation factor Von-Hippel Lindau syndrome
APC 5q21 binds / regulates P-catenin Familial adenomatous polyposis
INK4a 9p21 p16 -  cdk inhibitor, p19 - binds mdm2 Familial melanoma
PTC 9q22.3 transmembrane receptor for sonic hedgehog Gorlin syndrome
BRCA1 17q21 transcriptional regulator / DNA repair Familial breast cancer
BRCA2 13q12 transcriptional regulator / DNA repair Familial breast cancer
DPC4 18q21. 1 transduces TGF-P signals Juvenile polyposis syndrome
FHIT 3p14.2 nucleoside hydrolase Familial clear cell renal carcinoma
PTEN 10q23 lipid phosphatase / dual specificity phosphatase Cowden disease, BRR ,LDD
TSC1 9q34 cell adhesion regulator Tuberous sclerosis
TSC2 16 cell cycle regulator Tuberous sclerosis
NKX3.1 8p21 homeobox protein Familial prostate carcinoma
LKB1 19p13 serine / threonine kinase Peutz-Jeghers syndrome
E-Cadherin 16q22.1 cell adhesion regulator Familial gastric cancer
Functional studies implicated the RBI gene product in controlling transcription of genes, 
which are expressed during cell cycle progression. During the G1-phase dephosphorylated 
RB1 protein binds and inactivates a group of transcription factors collectively called E2F, 
which form heterodimers with the related E2F dimerization partner (DP) family of co­
activators. Upon entering the S-phase, RB1 is phosphorylated thereby relieving the repressive 
action of the E2F-DP heterodimers and releasing active E2F transcription factors. Completion 
of the cell cycle triggers dephosphorylation of RB1 which results in the recruitment of the 
E2F-DP transcription factors back into the RB1 complex (reviewed in [28, 29]). Loss of 
function mutations in the RBI -gene result in a continuously active E2F-DP dependent
- 12 -
Chapter 1
transcription, which removes the regulatory control mechanism at entering the S-phase. If this 
mechanism is absent cell cycle-arrest and DNA-repair (discussed in the next paragraph) are 
impossible, thereby increasing the risk of cancer development.
Another important contribution towards understanding the process of transformation came 
from detailed studies of the tumor suppressor gene p53 [30]. Apart from its involvement in an 
autosomal dominantly inherited cancer syndrome called Li-Fraumeni syndrome, which can be 
caused by p53 germline mutations[31], it is now clear that loss of or a mutation in the p53 
gene belongs to the most frequent alterations in human cancer (50-55%) [32]. A well- 
established function of p53 is that of being a transcription factor. As a tetramer, it recognizes 
specific p53-binding sites on DNA, thereby activating the transcription of target genes such as 
p21 and Bax. This increased transcription of downstream targets ultimately results in 
prolonged G1 arrest or apoptosis. Almost all naturally occurring mutations affect the DNA 
binding capacity of p53, illustrating the importance of this ability. Several signals of cellular 
distress are capable of activating p53 by posttranslational modifications, DNA damage being 
one of the most prominent. Upon DNA damage, sensed by upstream components of this 
pathway, p53 levels rise because of a significant increase in half-life. This (in)stability is 
dependent of MDM2, a negative regulator of p53 [33, 34]. Several kinases have been 
identified capable of phosphorylating p53, including ATM, ATR, Chk2 and DNA-PK [35­
38], although the latter has been excluded by in vivo data [39]. The phosphorylation of p53 at 
amino acids Ser15 and Ser20 induces a conformational change preventing the interaction with 
MDM2. One of the genes up regulated upon activation of p53 is p21 [40], which is capable of 
binding cyclinD-CDK4, thereby inhibiting the phosphorylation of the above-mentioned RB1. 
This process will block the transition of G1 to S phase in the cell cycle enabling the cell to 
repair DNA damage. Apoptosis is the other major response, which can be triggered by p53, 
and this response is often affected in many primary tumor cells. The decision of a cell to enter 
the apoptotic pathway depends on different stimuli, for instance on DNA damage [41] or the 
presence of an activated oncogene [42]. Unlike the cell cycle regulation by p53, the p53 
apoptosis induction mechanism remains largely unclear. Data indicate that p53 transcription 
dependent and independent mechanisms exist. For instance, a p53-regulated transcription of 
the death gene Bax, a known antagonist of the survival gene bcl-2, favors an apoptotic 
response [43]. Other p53 target genes implicated in apoptosis signaling are, among others, 
Fas/APO1 [44] and KILLER/DR5 [45]. Signals of these three target genes result in a 
downstream activation of a caspase pathway. However, inhibition of transcription or
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translation does not always affect p53-mediated apoptosis indicating p53 transcription 
independent mechanisms exist (reviewed in [30, 46]).
By using these cellular responses cells are capable to maintain and preserve the genome 
and elimination of derailed cells (unstable genomes, activated oncogenes) is possible. Loss of 
components functioning in these pathways leads to a deregulation of the cell cycle, genome 
instability and a predisposition to cancer development.
1.4 Mutator genes
A major factor in tumorigenesis is genetic instability and this instability is a necessity for 
somatic cells to transform to full malignant cells. Besides oncogenes and tumor suppressor 
genes a third class of genes, the mutator genes, is commonly mutated in human cancer. These 
genes play an important role in maintaining the genetic information by functioning in DNA 
replication and repair of DNA. One typical consequence of mutations in genes guarding the 
fidelity of DNA replication is the occurrence of microsatellite instability (MIN). This 
phenotype was first discovered in tumors of HNPCC and linked to a human homologue 
(hMSH2) of the mismatch repair (MMR) gene in yeast, MutS [47, 48]. The hMSH2 protein is 
capable of recognizing and restoring mismatches that occur during DNA replication. A result 
of the presence of a germline mutation and somatic loss of the wild type allele is the early 
development of gastrointestinal and genitourinary tract tumors. Defects in other MMR genes 
associated with HNPCC were rapidly identified after this initial discovery [49, 50]. Apart 
from instability at the DNA level, tumor cells often show chromosomal instability as well. 
Several rare cancer syndromes have been identified and the genes responsible have been 
cloned, such as the gene involved in Bloom syndrome (BLM) located at 15q26.1 [51] and the 
Ataxia-Telangiectasia (ATM) gene at 11q22 [52]. Other genes functioning in DNA 
maintenance are the XPA, XPB associated with Xeroderma Pigmentosum [53, 54], and several 
of the genes involved in Fanconi’s Anaemia, FACA, FACC, FACG, FACF [55-58]. The 
common theme of these genes is that they are all involved in maintenance of the genome and 
that loss of their function predisposes to various types of abnormalities and cancer.
1.5 A functional classification
The search for genes predisposing to cancer when mutated has resulted in the identification 
of several genes that act as “gatekeepers’’ [4, 59]. It was hypothesized that gatekeeper genes
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are responsible for maintaining a constant cell number. A mutated gatekeeper in one cell 
would lead to clonal cell proliferation in a given tissue. However, genetic mutations in other 
genes in the presence of a functional gatekeeper would not result in a growth imbalance. For 
instance, complete inactivation of the APC gene, identified as the gene involved in familial 
adenomatous polyposis (FAP), has been found in the earliest precursor lesions of 
adenomatous polyps [60]. This indicates the initiation of the neoplastic process. In contrast, 
although p53 is mutated in the majority of colorectal cancers [61], there is no clinical 
evidence of an increased risk for colorectal cancers in Li-Fraumeni syndrome [62]. This 
exemplifies that, although p53 does play a role in colorectal cancer, absence of a functional 
protein cannot initiate the neoplastic process similar to the absence of APC.
LKB1/STK11 might be another example of a gatekeeper gene. This gene is involved in 
Peutz-Jeghers syndrome (PJS); a hamartomatous syndrome typified by hamartomatous polyps 
of the intestine and mucocutaneous pigmentation with an increased risk of breast, testis, 
ovary, and gastrointestinal cancer. LKB1/STK11 encodes a serine/threonine protein kinase 
[63, 64]. The nature of the identified mutations is consistent with LKB1/STK11 being a tumor 
suppressor gene [65]. Inactivation of this gene was found in gastrointestinal hamartomas and 
adenocarcinomas while no mutations in genes or chromosomal regions known to be 
frequently involved in colorectal cancer were detected [65]. The function of the “gatekeeper” 
is lost in PJS thereby allowing the cells to progress to the early precursor lesion and additional 
hits will lead to a cancerous outgrowth.
The term “caretakers” was introduced for genes involved in the maintenance of the 
integrity of the genome. Inactivation of these genes, also known as mutator genes (see above), 
contributes indirectly to neoplastic outgrowth because of the resulting high mutation rate. In 
contrast to a gatekeeper gene, restoration of the caretaker function will not affect tumor 
growth and they are rarely mutated in sporadic cancer.
A third category of genes has been called “landscapers”. Members of this class act 
indirectly as cancer susceptibility genes. The recent elucidation of the molecular basis of one 
of the hamartomatous polyposis syndromes, Juvenile Polyposis syndrome (JPS), has given 
some new insights. The morphology of the hamartomatous polyps in this syndrome is 
different compared to the polyps seen in FAP and HNPCC. Even if the polyps are compared 
to intestinal polyps of other hamartomatous polyposis syndromes there is a difference in 
morphology. In JPS, polyps are largely composed of stromal cells and, initially, the 
epithelium lacks dysplasia. It has been shown that indeed the stromal cells harbor the clonal 
expansion [66]. In contrast, in PJS it was shown that the epithelial cells harbor the genetic
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alteration [64]. The neoplastic stromal cells might drive the epithelial proliferation and 
thereby induce malignancies. As a consequence, the epithelial cells have an increased risk to 
undergo malignant transformation because of a change in the microenvironment surrounding 
the epithelium [59].
1.6 Outline of this thesis.
During the last decade our understanding of the mechanisms that lead to cancer has 
benefited from studies that aimed to identify genes involved in familial cancer syndromes 
(this chapter). As described above the approach that led to the identification of the RB1 gene 
has served as the prototype in the research on familial cancer predisposition. A specific group 
of familial cancer syndromes is called phakomatosis, hereditary diseases involving all three 
germinal layers and the formation of hamartomas/neoplasms capable of malignant 
transformation. Members of this group include neurofibromatosis, tuberous sclerosis, von 
Hippel-Lindau disease and the subject of this thesis, Cowden disease (CD). The genes 
involved in the first three syndromes have been cloned and their functions have been 
elucidated. They are all tumor suppressor genes involved in either growth or transcription 
regulation.
The identification of the gene involved in CD and the description of its function are subject 
of this thesis. Our first objective was to determine the chromosomal location of the 
gene/genes involved in CD. Linkage analysis in 12 families enabled us to assign a 
chromosomal location, 10q22-23, with a maximum lodscore of 8.92 (appendix 1). 
Subsequently, we set out to identify the CD gene by reducing the critical region and by 
positional cloning strategies and the positional candidate gene approach. Using the latter 
approach we were able to exclude a gene encoding a translation initiation factor, 4E-BP2 
(10q21-q22), and the gene encoding Vinculin, which is involved in cell-cell and cell-matrix 
interactions (10q22.1-10q23).
Three different groups identified the PTEN/MMAC1/TEP1 gene, phosphatase and tensin 
homologue deleted on chromosome 10 (PTEN) /  mutated in multiple advanced cancers 1 
(MMAC1) /  transforming growth factor-fi-regulated and epithelial cell-enriched phosphatase 
(TEP1) encoding a dual specificity phosphatase (referred to as PTEN hereafter) and this gene 
mapped within the Cowden critical region. Mutation analysis revealed that germline 
mutations identified within this gene are indeed causative for CD (appendix 2). After this 
initial mutation analysis we performed an extensive mutation screening in additional sporadic
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and familial CD patients to get more insight in the mutational spectrum of PTEN and to 
address a possible genotype-phenotype correlation (appendix 3). Since then two 
hamartomatous syndromes have been attributed to PTEN germline mutation, CD and 
Bannayan-Riley-Ruvalcaba (BRR) syndrome. Clinical characteristics of CD and BRR overlap 
and are likely due to differences in genetic background. Identical mutations have been 
identified in both phenotypes making differences in genetic background the most likely 
explanation. This variation in expression, even within families, makes it possible that 
CD/BRR represent only a part of the phenotype associated with PTEN germline mutations. To 
explore this possibility we evaluated both clinical data and PTEN mutation analysis of 
patients offered for genetic testing (appendix 4).
After its discovery, it became quickly apparent that PTEN was involved in a large variety 
of sporadic tumors. In fact, LOH studies had pointed the way to the identification of the 
PTEN gene. One tumor type that frequently shows PTEN alterations is the glioblastoma. 
Mutations are only occasionally detected in the less malignant gliomas. High-grade 
oligodendroglial tumors were rarely included in these studies. Since there are two genetic 
subtypes of oligodendroglial tumors, one containing a complete or partial deletion of 
chromosome 10, we have analyzed the involvement of PTEN in this genetic subtype 
(appendix 5).
A large number of CD patients show developmental abnormalities of which hypertrophy of 
the brain is the most prominent one. Other less frequent developmental abnormalities in CD 
patients are hypertrophy of breasts, hands and feet, and of the cranial facial bones. The high 
frequency of megalencephaly suggests an important role of PTEN in brain development. To 
gain more insight into the function of PTEN during development we examined the expression 
profile of PTEN using RNA in situ hybridization during mouse development and postnatal 
brain development (appendix 6).
The next chapter gives an overview of the new insights and the tremendous progress made 






Chapter II: Identification of the Cowden disease gene and its function in 
tumorigenesis and development 
II.1 Cowden disease, the clinical picture
Lloyd and Dennis described the first case of CD in 1963 [67]. The name of this entity 
refers to the family name of the patient they described, Rachel Cowden. The most striking 
clinical features included: oral papillomatosis, scrotal tongue, thyroid adenomas, fibrocystic 
disease of the breast, and abnormalities of the central nervous system. Furthermore, similar 
clinical findings were present in other family members [67]. Since its initial description, 
several hundred additional cases of this rare entity have been reported. Weary et al. [68] 
suggested an alternative name, multiple hamartoma syndrome, because of the variety of 
benign lesions (hamartomas) that can be found predominantly in the skin, the mucous 
membranes, the thyroid, the breast, and the gastrointestinal tract [68]. In addition, Weary et al. 
identified an autosomal dominant pattern of inheritance in the family of Rachel Cowden. 
Studies in additional families confirmed this mode of inheritance and exhibited a high 
penetrance of CD [69].
The clinical picture of CD is heterogeneous among patients, also within families. Both 
benign and malignant neoplasms develop at variable frequencies and at various locations. The 
age of onset of CD may vary but commonly signs occur in the 2nd or 3rd decade of life [69], 
although progressive macrocephaly is a sign in young children [70]. Pathognomonic for CD is
Figure 1: CD characteristic skin and mucosal lesions: palmoplantar keratosis, facial papules 
and multiple oral papilomatosis
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the presence of multiple facial trichilemmomas [71]. A combination of this benign tumor of 
the outer root sheath of the hair follicle and other characteristic skin and mucosal lesions, e.g. 
facial papules, acral keratosis, multiple oral papillomas, palmoplantar keratosis, is the most 
frequent diagnostic hallmark of CD and is reported in more than 95% of the patients (fig.1) 
[72].
Very frequent is also the occurrence of benign breast lesions in female patients. About 70­
90% of the women show features of a breast hamartoma and 60-70% develop fibrocystic 
disease of the breast [73, 74]. Other organ systems, which develop benign lesions, are the 
female genitourinary tract, the thyroid and the digestive tract. In about 70% of the patients, 
involvement of the thyroid gland is seen which usually manifests as either goiter or thyroid 
adenoma [72, 73, 75]. Intestinal polyps are reported to be found in ~75% of the patients from 
whom the gastrointestinal tract is fully evaluated [76].
The gravity of CD lies in the increased risk to develop malignant neoplasms. The highest 
risk is found for breast cancer. Recent studies indicate that 30-75% of the female CD patients 
show malignant disease of the breast [69, 70, 74]. Furthermore, about 7% of the CD patients 
(7%) develop follicular thyroid adenocarcinoma and about 3% develop colonic malignancies 
[70, 75]. Other malignancies such as uterine, ovarian, lung, cutaneous and renal cell 
carcinomas, are observed with increased frequencies as well.
Besides the hamartomas and other neoplasms, symptoms of CD include several 
developmental abnormalities. Hypertrophy of hands, feet and breasts are occasionally found, 
and megalencephaly is detected in a large portion of the patients. Neurological abnormalities 
in CD did not obtain much attention, although such features, e.g. poor coordination and low 
intelligence, were mentioned in the initial report by Lloyd and Dennis [67]. In a large clinical 
study Starink et al. reported macrocephaly in 80% of the CD cases [69], making 
macrocephaly the most frequent symptom next to the typical skin lesions. Moreover, 
progressive macrocephaly in combination with mental retardation is an important indication 
of CD in young children [70]. This macrocephaly was identified as a true megalencephaly 
without clear histological abnormalities [77]. Another important neurological feature 
observed in a subset of the CD patients is a hamartomatous lesion of the cerebellum, known 
as Lhermitte-Duclos disease (LDD) [78]. This rare abnormality is characterized by 
hypertrophic ganglion cells in a disorganized granular layer of the cerebellum with only a few 
Purkinje cells present and a thickening of the molecular layer. Patients frequently present an 
increased intracranial pressure or cerebellar dysfunction (e.g. ataxia, coordination problems). 
The observation of the presence of a dysplastic gangliocytoma (LDD) and CD in two
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unrelated patients suggested that LDD and CD are part of the same entity and established CD 
as a true phakomatosis [79].
II.2 A molecular genetic approach
Many genetic studies have been performed to elucidate the cause of CD. Lloyd and Dennis 
studied the karyotype of the initial patient [67] and this has also been performed in other CD 
patients. However, in general the karyotype of CD patients is normal. Only a few reports exist 
on chromosomal anomalies. One patient showed a pericentric inversion of chromosome 9 [69] 
and an association with Down syndrome has been reported [80]. DNA repair-studies using 
fibroblasts of two affected individuals did not reveal any abnormality [69]. Also, a search for 
DNA mutations, rearrangements and/or amplifications of several genes including epidermal 
growth factor receptor (EGFR), the ras oncogene, the Her-2/neu oncogene, and pS-2 did not 
give any clues [73, 81]. Furthermore, SSCP analysis of the p53 tumor suppressor gene failed 
to detect any mutation [82].
Two initial linkage studies, performed in three families, using the HLA locus and thirteen 
other informative loci located on various chromosomes did not reach significant lodscores 
[69, 83]. Our linkage study, a genome scan using a total of twelve CD families, resulted in the 
localization of a CD gene to chromosome 10q22-23. The maximum lodscore of 8.92 at 0 =
0.02 was reached with the marker D10S573. Haplotype construction defined the most likely 
position of the CD gene in a 5 cM interval between D10S215 and D10S564 [84] (appendix 1). 
No evidence for genetic heterogeneity was found in this study. However, there is one report 
that suggests the existence of genetic heterogeneity for CD based on additional linkage data 
[85].
Allelic losses involving the long arm of chromosome 10 suggested the existence of one or 
more tumor suppressive loci in the 10q22-25 region. Tumors showing this loss are prostate, 
renal, small cell lung and endometrial carcinomas, melanomas, and glioblastomas [86-91]. 
Mapping of homozygous deletions on chromosome 10q23 present in glioma cell lines and 
breast tumors has led to the identification of a tumor suppressor gene, PTEN/MMAC1/TEP1 
[92-94]. This gene consists of 9 exons, encoding a 403-amino acid protein with a tyrosine 
phosphatase domain and has sequence homology with tensin and auxilin, and mapped within 
the Cowden critical region. Tensin, a protein involved in actin binding, localizes to focal 
adhesion complexes. Auxilin is involved in the uncoating of clathrin-coated vesicles. These 
data established PTEN as a likely candidate gene involved in CD.
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Detection of germline mutations in patients with CD showed that PTEN is indeed the gene 
for CD [95, 96](appendix 2). A mutation is detected in approximately 80% of the CD patients. 
PTEN mutation analysis failed to identify alterations in the coding sequence in a substantial 
number of patients [97, 98] (appendix 3). This might be explained either by mutations present 
in introns or in the promotor region of the PTEN gene or, as argued above, indicate genetic 
heterogeneity.
Germline mutations have also been found in two other members of the family of 
hamartomatous polyposis syndromes namely Bannayan-Riley-Ruvalcaba (BRR) syndrome 
[99, 100] and in juvenile polyposis syndrome (JPS) [101]. Symptoms of BRR partially 
overlap with those seen in CD (mainly macrocephaly, intestinal hamartomatous polyps, 
lipomas, and heamangiomas) and the identification of similar mutations in both BRR and CD 
suggests that these two syndromes represent a variable spectrum of one hereditary cancer 
syndrome [98, 102]. This was underscored by the identification of PTEN mutations in 
families in which both CD and BRR were diagnosed [103]. JPS is the third entity, 
characterized by the development of hamartomatous polyps throughout the digestive tract and 
a predisposition to digestive tract cancer. PTEN germline mutation have been identified in 
JPS patients [101], although it has been argued that these cases could very well be diagnosed 
as either CD or BRR patients [104]. In fact, in one family both JPS and CD were diagnosed 
[105]. Furthermore, the identification of SMAD4 as another gene mutated in JPS [106] 
confirmed earlier observations of genetic heterogeneity [107, 108]. At any rate, a role of 
PTEN in JPS remains the subject of debate.
Germline mutations in the PTEN gene are scattered over the entire protein coding sequence 
with an accumulation of mutations in exon 5, which encodes the phosphatase active site. No 
mutation seems to be linked to a specific phenotype [97, 98], although the presence of a 
PTEN mutation in a CD family was suggested to be associated with the occurrence of breast 
cancer [98]. However, we were unable to confirm this association [97] (appendix 3). The 
absence of clear genotype-phenotype correlations and the marked variation of CD expression, 
even within families, support the idea of the existence of modifier genes, which is underlined 
by the presence of both CD and BRR in the same families. Taken together, these data suggest 
that the genetic background plays a primary role in determining the spectrum of abnormalities 
given a certain PTEN mutation. This hypothesis is supported by the differences in phenotypes 
identified in PTEN deficient mice [109-112].
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11.3 PTEN and non-hereditary cancer
As mentioned above, loss of heterozygosity (LOH) at chromosome 10q, in particular at the 
10q22-25 region, has been described for a large number of sporadic human cancers. 
Furthermore, these deletion studies indicated that LOH at 10q is a frequent event in the more 
advanced stages of tumor development [89-91, 113]. The hypothesis that this region harbors 
at least one tumor suppressor gene was confirmed with the cloning of PTEN [92, 93].
After the initial cloning reports describing PTEN mutations in glioblastoma, breast cancer, 
and prostate cancer cell lines mutations were also found in primary tumors of the breast, 
prostate and glioblastomas. Subsequent analysis of a large variety of tumors confirmed that 
PTEN is frequently mutated in human cancer. In glioblastoma multiforme, it became apparent 
that up to 30% of the primary tumors carry a mutation in the second allele if the tumor 
displays LOH [114-116]. In line with earlier observations, prostate tumors of a high grade are 
likely to harbor PTEN mutations and/or LOH, identifying PTEN as the main inactivation 
target of chromosome 10q in sporadic prostate cancer [117, 118]. PTEN inactivation is also 
detected in primary malignant melanomas with a frequency of up to 50% in melanoma cell 
lines [119]. In endometrial carcinomas, PTEN turned out to be the most frequently mutated 
gene so far [120-122]. In contrast to other tumor types however, mutations were detected in 
all stages of endometrial cancer suggesting that the inactivation of PTEN is an early event in 
endometrial carcinogenesis. In fact, 30% of complex atypical hyperplasias, the direct 
precursors of endometrial cancer, show PTEN alterations [123].
Although PTEN mutations were identified in breast cancer cell lines [92, 93, 124], 
mutations in primary tumors of sporadic breast cancer patients are only found in a minor 
fraction [125-128]. Also, in familial breast cancer germline mutations in PTEN seem to play a 
minor role, despite the increased incidence of breast cancer in CD [129-132]. However, LOH 
encompassing the PTEN region is frequently detected in primary breast carcinomas pointing 
to the presence of yet another tumor suppressor gene in the distal part of chromosome 10 
[127]. Also mutation analysis of small cell lung cancers (SCLC), non-small cell lung cancers 
(NSCLC), several head and neck cancers (HNSCC), and meningiomas support this 
assumption, since these tumors are associated with chromosome 10q abnormalities, but 
mutations in PTEN are not detected or at low frequencies [116, 133-135]. A second tumor 
suppressor gene from 10q is indeed identified, namely DMBT1 located on 10q25.3-26.1. 
Mutations in this gene were detected in low-grade gliomas suggesting early involvement in 
glioma oncogenesis, this in contrast to PTEN [136].
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All together, PTEN mutation analysis indicates that it is one of the most frequently mutated 
genes in human cancer with mutation frequencies comparable to that of p53.
11.4 Kinases, phosphatases, and tumorigenesis.
Protein phosphorylation and dephosphorylation are vital and primary tools of a cell to 
control cellular signaling networks that control cell growth and differentiation and they enable 
cells to respond to their environment. Because both kinases and phosphatases are integral 
components of these dynamic signaling networks, these enzymes are likely to play an 
important role in tumorigenesis. In fact, the link between protein phosphorylation and cancer 
was firmly established when the src-oncogene product was identified as a protein tyrosine 
kinase (PTK) [137]. After this initial observation, many other protein kinases were identified 
as (proto-)oncogenes (chapter 1). In contrast, only few protein kinases have been identified as 
tumor suppressor genes. Many of the protein kinases have been identified as retroviral 
oncogenes. Their cellular counterparts are almost invariably activated through somatic 
mutations in tumors. As discussed in chapter 1 protein kinases can be activated / inactivated 
by several mutational events such as amplification, deletion, mutation of regulatory domains, 
or genetic rearrangement resulting in an oncogenic fusion protein.
Only very few phosphatases have been implicated in tumorigenesis thus far [138]. It has 
been postulated for a long time that some of the protein tyrosine phosphatases, as antagonists 
of PTKs, could act as tumor suppressor genes. However, in contrast to protein kinases, the 
contribution of protein phosphatases falls short of these expectations. In fact, PTEN was the 
first phosphatase identified as a tumor suppressor and established the link that was expected 
between phosphatases and growth regulation and tumorigenesis (see above). The pathway by 
which PTEN mediates this growth control involve at least two known proto-oncogenes: 
phosphatidylinositide 3-kinase (PI3K) and the cellular homologue of v-Akt, protein kinase 
B/Akt. This PI3K/Akt signaling pathway controls and coordinates cell growth and survival 
[139].
11.5 PTEN and its function
As mentioned above, sequence analysis of the PTEN cDNA revealed the highly conserved 
protein tyrosine phosphatase (PTPase) signature motif HCXXGXXRS/T (X = any amino 
acid), a motif characteristic for all PTPase family members. PTPases can be subdivided into
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two distinct groups: “classic” PTPases selective only for phosphotyrosine and the so-called 
dual specificity phosphatases selective for phosphotyrosine, phosphoserine and/or 
phosphothreonine [140]. An important factor in reaching this substrate specificity is the 
location of the required catalytic cysteine in the active site cleft [141, 142]. A significant 
number of both sporadic and germline PTEN mutations seem to cluster in exon 5 which 
encodes the catalytic phosphatase domain and flanking amino acids, underlining the 
biological importance of this domain for PTEN. Also, sequences homologies outside the core 
domain suggest that PTEN is a member of the dual specificity phosphatases [92, 93].
The first and a key step in unraveling PTEN’s function was the observation by Myers et al. 
that recombinant-PTEN showed a strong preference towards the most acidic peptide 
substrates [143]. Dual specificity was shown by the exhibition of phosphatase activity against 
both serine/threonine and tyrosine phosphorylated substrates [143]. Moreover, using the same 
assay they were able to show that PTEN phosphatase activity for these peptides was lost by 
most of the previously described PTEN mutations, with the exception of the G129E mutation. 
This mutation was identified in two independent CD cases indicating a loss of PTEN 
function. Thus, this mutation could be used to identify relevant substrates.
Early studies determining the potential function of PTEN suggested a role in cell 
migration, cell spreading and the formation of focal adhesions [144]. Growth suppression was 
shown by the introduction of wild-type PTEN in glioma cells that contained endogenous 
mutant PTEN alleles [145]. Sequence similarities of PTEN to tensin, an actin filament binding 
cytoskeletal protein which is phosphorylated upon integrin-mediated cell adhesion, seemed to 
be of functional importance. Indeed, it was shown by overexpression studies that PTEN is 
capable of inhibiting cell migration and that PTEN interacted with focal adhesion kinase 
(FAK) thereby reducing its tyrosine phosphorylation [144]. A strong argument for other 
PTEN targets than FAK was the fact that again the CD-allele G129E, unlike other mutant 
PTEN alleles, retained its FAK phosphatase activity in these cell spreading assays, indicating 
that dephosphorylation of FAK is, at least in CD, not the main issue. This discrepancy 
between the retention of the PTP activity and the disease causing effect of the G129E CD- 
allele was solved with the identification of phosphatidylinositol 3,4,5-triphosphate (PtdIns-
3,4,5-P3) as a substrate of PTEN [146]. This lipid phosphatase activity of PTEN was shown to 
be the essential activity necessary for its tumor suppressive ability. PTEN mutant alleles, also 
the PTEN-G129E allele, are unable to dephosphorylate PtdIns-3,4,5-P3 [147]. The PTEN 
dephosphorylation activity is specific for position D3 of the inositol ring. Several mutations 
involving the catalytic cysteine have been reported and a C124S mutated PTEN resulted in a
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complete loss of the lipid phosphatase activity [146]. This indicates that the cysteine residue 
is essential for activity thereby implying a lipid dephosphorylation mechanism, which is 
comparable to that of PTPases with proteinaceous substrates [140]. Indeed, the PTEN crystal 
structure shows a wider but similar active site pocket providing sufficient space to 
accommodate PtdIns-3,4,5-P3 [148].
II.6 Mechanism and consequences
Previous studies have shown that the oncogenic PI3K is able to phosphorylate the D3 
position of the inositol ring to produce phosphatidylinositol-3-P (PtdIns-3-P), PtdIns-3,4-P2 
and PtdIns-3,4,5-P3. The lipid phosphatase activity of PTEN shows specificity for these 
products with highest affinity towards position 3 on the inositol ring of PtIns-3,4,5-P3 [146, 
147] and it is therefor that PTEN functions as an antagonist of PI3K. The generation of 
PtdIns-3,4,5-P3 by PI3K leads to several downstream events, such as the 
translocation/activation of PKB/Akt. This protein is a serine/threonine kinase and contains a 
functionally important pleckstrin homology (PH) domain. PKB/Akt can be activated in 
response to several stimuli, for instance insulin, IGF-1, and this activation can be inhibited 
through inhibition of PI3K or by overexpressing dominant negative forms of PI3K [149, 150]. 
Recently, the mechanism behind this activation has been elucidated: the PH domain of 
PKB/Akt has an affinity for both PtdIns-3,4,5-P3 and PtdIns-3,4-P2 [151, 152]. The important 
aspect of this affinity is the translocation of PKB/Akt to the plasma membrane in response to 
PI3K activation [153]. This recruitment to the plasma membrane also induces a 
conformational change providing two 3-phosphoinositide-dependent kinases, PDK1 and 
PDK2, access to two phosphorylation sites (Thr308 and Ser473). Phosphorylation of the two 
sites activates PKB/Akt [154]. PDK2 was recently identified as the integrin-linked kinase 
(ILK) [155].
As described above, loss of PTEN function leads to increased levels of PtdIns-3,4,5-P3, 
which results in an increased recruitment and activity of the proto-oncogene PKB/Akt. 
Indeed, several experimental lines of evidence show that PTEN-deficient glioblastoma and 
prostate tumor cell lines have increased levels of PtdIns-3,4,5-P3 and activated PKB/Akt [147, 
156-159]. An important function of PKB/Akt is the regulation of cell survival [139, 160]. 
Consistent with this is the observation that mPten deficient fibroblasts show a reduced 
sensitivity to apoptotic stimuli. This resistance to apoptosis could be countered by the 
introduction of wild type PTEN. Furthermore, a constitutively active form of PKB/Akt
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rescued cells from PTEN induced apoptosis [161]. One of the known cellular targets through 
which PKB/Akt can protect cells from apoptosis is phosphorylation of the pro-apoptotic 
protein BAD [162, 163]. In fact, it has been shown that in PTENT-' glioblastoma cell lines 
reintroduction of PTEN leads to a reduction of PKB/Akt activity evident from reduced 
phosphorylated levels of BAD [147]. However, because of the limited number of tissues that 
express BAD additional PKB/Akt targets functioning in the apoptotic pathway are to be 
expected [164]. Recently, indeed two additional PKB/Akt substrates have been identified, the 
protease Caspase 9 [165] and a member of the Forkhead transcription factor family, FKHRL1 
[166]. In both cases, phosphorylation of these proteins by PKB/Akt suppresses their 
proapoptotic function. Thus, loss of PTEN has an anti-apoptotic effect via these pathways.
It is evident from a number of studies that PTEN is also involved in the regulation of cell 
cycle progression [156, 167, 168]. PTEN overexpression results in a reduction of cell 
proliferation [156, 157], a process that can be mimicked by inhibiting PI3K with wortmannin, 
and this results in a block of G1 cell cycle progression [169]. Together with this growth arrest 
an upregulation of cyclin-CDK inhibitor p27(KIP1) occurs and this is dependent on PTEN 
phosphatase activity [156]. Moreover, this PTEN-induced growth arrest is antagonized by 
activated PI3-K or downstream targets such as AKT or PDK1 [170]. Taken together, these 
studies suggest that the PTEN tumor suppressor modulates G1 cell cycle progression through 
negatively regulating the PI3K-PKB/Akt signaling pathway, and that one critical target of this 
signaling process is the cyclin-dependent kinase inhibitor p27(KIP1).
As stated earlier, the lipid phosphatase PTEN possesses also protein phosphatase activity. 
A role in cell adhesion and migration was revealed through direct PTEN interaction with and 
dephosphorylation of the focal adhesion kinase (FAK) and the SH2-phosphotyrosine adapter 
protein Shc [144, 171, 172]. It was found that the PTEN mutant G129E is still active as a 
protein phosphatase reducing the phosphorylation status of FAK, thereby affecting the 
processes mentioned above. This feature is lost by the C124S mutant, which lacks both the 
lipid and the protein phosphatase activity [144]. However, conflicting data question the 
involvement of the PTEN protein/lipid phosphatase activity in cell adhesion and migration 
through FAK signalling [173]. FAK phosphorylation levels were not altered by 
overexpressing wildtype PTEN or a phosphatase deficient PTEN in invasive glioma cell lines 
lacking a functional PTEN. Also in Pten deficient mouse ES cells no differences in FAK 
phosphorylation could be detected in comparison to wildtype ES cells [168].
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Overall, PTEN is involved in various cellular responses by controlling the levels of PtdIns-
3,4,5-P3, thereby regulating the activity of PKB/Akt, and possibly by direct 
dephosphorylation of target proteins like FAK and Shc.
Figure 2: Schematic representation of the mode of action of PTEN in the control of cell pro-
Several groups have identified the C. Elegans homologue of PTEN, DAF-18 [174-177]. In 
C. Elegans, an insulin-like receptor pathway is known and homologues of the PI3K (AGE-1) 
and PKB/Akt (AKT1, AKT2) have been shown to function in this cascade. This pathway 
modulates dauer formation and lifespan of the nematodes [178, 179]. Loss of function 
mutations in either DAF-2 (insulin-like receptor homologue) or AGE-1 result in the 
continuous formation of dauer larvae [179]. It has been shown that DAF-18 can suppress this 
phenotype and thus antagonizes the DAF-2/AGE-1 pathway [174-177]. Given the 
preservation of this AGE-1/PI3K signaling pathway, nematodes can be of importance to 
further elucidate the function of the human PTEN.
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Also the Drosophila homologue of PTEN (DPTEN) has been cloned and characterized 
[180, 181]. The genetic studies have demonstrated that DPTEN has a control function that 
affects both cell size and number. It was shown that DPTEN acts antagonistically to the 
Drosophila homologue of PI3K, Dp 110. Loss of DPTEN results not only in an increase in 
cell number but also in larger cells [180, 181]. Recent characterization of several components 
of the insulin pathway, including chico, Inr, and PI3K underline the important role of this 
signaling cascade in regulating cell number and size [182, 183]. DPTEN mutant cells show 
also a disturbed actin cytoskeletal organization, although the mechanism behind this 
disorganization remains unclear. Interestingly, Dp110 overexpressing cells do not show this 
phenotype, indicating this is not the result of increased levels of PtdIns-3,4,5-P3 [181].
II.7 PTEN and mouse development
To study the role of PTEN in normal development and tumorigenesis, three groups have 
created mouse models and introduced different deletions into the Pten gene [109, 110, 112]. 
All three Pten-deficient mouse models resulted in a disorganization of the early embryo and 
embryonic lethality although the time of embryonic death differed (E7.5-E9.5). Pten-deficient 
embryonic bodies revealed a marked disorganization in the three germinal layers [110].
Heterozygous mice were examined and it is evident that Pten+I- mice have increased tumor
3-5susceptibility. Tumors detected in the various mouse models differ. The heterozygous Pten " 
mouse (exon 3 to 5 deleted) frequently developed T-cell lymphomas, but also colonic polyps, 
prostate, liver, endometrial and germline tumors were detected [109]. The mouse model Pten4' 
5 (exon 4 and 5 deleted) also showed a marked increase in tumor formation. Colon 
carcinomas, testicular and germline tumors, and thyroid carcinomas were detected. 
Interestingly, several mice showed hyperplasia/dysplasia in the gastrointestinal tract, prostate, 
testis and skin [110]. A major finding in these Pten4-5 heterozygous mice was the impaired 
FAS-mediated apoptosis in activated lymphocytes. The sensitivity to FAS could be restored 
by treating the cells with PI3-kinase inhibitors like wortmannin, implicating the PI3-kinase 
pathway in FAS responsiveness. Strikingly, Pten haplo-insufficiency in these mice also 
resulted in a lethal autoimmune disorder [111]. The third Pten mouse model, containing a 
deletion of exon 5 developed neoplasms in multiple organs. Neoplasms of the thyroid, 
prostate, liver and endometrium were found together with intestinal polyps and lymphomas. 
Also these mice displayed an apoptotic defect, detected in B cells and macrophages [112]. 
These observations, complemented with the frequently detected LOH in the examined tumors,
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confirmed the PTEN status as a tumor suppressor gene. It is unlikely that the phenotypic 
differences in the three mouse models are caused by the nature of the mutations used. Thus, a 
likely explanation for this is the difference in genetic background present in the various 
mouse models.
Essential features of CD are the development of hamartomas, megalencephaly 
(overgrowth), and increased tumor susceptibility. The detected dysplasia/hyperplasia might be 
considered as a hamartomatous-like outgrowth and in combination with the increased 
incidence of tumors, the Pten-deficient mice appear suitable models to study tumor 
development. However, none of the Pten+I- mice showed goiter or breast cancer. Neurological 
signs such as megalencephaly and LDD were, although not studied in great detail, also not 
reported. This discrepancy between the effect of PTEN deficiency in humans and mice 
requires further study.
The presence of developmental defects, mainly macrocephaly, in a large number of CD 
patients, indicate that PTEN function is of importance during development, emphasized by 
early embryonic lethality in Pten-deficient mouse models. To get further insight into the 
possible role of PTEN during mouse embryonic development and postnatal brain 
development RNA in situ experiments have been performed [184] (appendix 6). Early 
embryonic development (E7-E11) is marked by a ubiquitous PTEN expression [184]. During 
further development this general expression is still present but several tissues stand out and 
their PTEN-expression levels become more pronounced. These tissues include the thymus, 
multiple ganglia (in particular the dorsal root ganglia), the thyroid gland, the developing 
follicles of the vibrissae, the skin and the epithelia of the tongue and the intestine. During 
postnatal brain development the highest PTEN mRNA levels are detected in the hippocampus, 
the olfactory bulb, the cerebral cortex and the cerebellum. Also, upon maturation of the brain 
the expression levels become more differentiated (appendix 6.).
In summary, the organs and tissues with a higher PTEN expression correlate with those 
affected in CD patients. However, high expression in the thymus and dorsal root ganglia do 
not reflect symptoms of CD. Thymic lesions are rarely detected in CD patients, likely because 
symptoms usually develop in the second or third decade of life at which time the thymus is 
already degenerated. Also in heterozygous knockout mice development of ganglia related 
neoplasms have not been reported.
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Chapter III: Conclusions, discussion, and future prospects
In the past few years, there has been a tremendous progress in both the genetics of CD and 
the functional aspects of the CD gene PTEN. It is now clear that PTEN is the major gene 
involved in CD. Approximately 80% of the patients carry a germline mutation in the PTEN 
protein coding sequence or splice sites of the PTEN gene [97, 98]. Furthermore, it has been 
confirmed both by clinical studies, linkage studies and mutation analysis that LDD and CD 
are part of the same entity and that the dysplastic gangliocytoma of the cerebellum can be 
considered as a central nervous system manifestation of CD. In addition, Bannayan-Riley- 
Ruvalcaba syndrome can be regarded as being part of this entity since identical mutations 
have been identified in both CD patients and BRR patients. Moreover, both CD and BRR 
have been diagnosed in the same families [103]. The difference in expression of PTEN 
mutations is likely due to differences in genetic background and remains subject of further 
investigation.
Still, a fairly large number of CD patients do not have a mutation in the PTEN coding 
sequence or intron/exon boundaries. Apart from the presence of mutations in the non-coding 
regions, such as the creation of alternative splice sites in intronic sequences or promoter 
mutations, genetic heterogeneity has been suggested. In line with this hypothesis is the fact 
that CD families have been reported which are not linked to the Cowden critical region [85]. 
Analogous to other cancer syndromes in which genes of the same pathway are involved one 
might expect mutations in other genes that result in a deregulation of the PI3K signal 
transduction pathway. In addition, mutations might be expected in genes encoding proteins 
involved in the regulation of PTEN activity.
Not much information exists on the regulation of PTEN apart from the down-regulation of 
the gene by TGF^ [94]. Since the main function of PTEN is to regulate PtdIns-3,4,5-P3 levels 
one can anticipate a tight regulation of the translocation of cytoplasmic PTEN towards the 
plasma membrane. In line with this, the C-terminal region of PTEN is the target of a 
substantial number of mutations both in CD patients and in tumors. One domain involved in 
membrane localization of PTEN is a C2 domain, which is present in the C-terminal part of the 
protein. C2 domains are known to mediate membrane association and it has been shown that 
indeed mutations in this part of the protein affect PTEN affinity towards phospholipid 
membranes [148]. Another motif, which might be involved in the subcellular localization of 
PTEN, is the potential PDZ binding target present at the protein’s C-terminus. PDZ domains 
are known to function in the formation of multiprotein complexes by binding to specific C-
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terminal tetrapeptides. Yeast two-hybrid searches with the PTEN C-terminal tail identified 
several interactors. Among them was the human homologue of the Drosophila disc large 
tumor suppressor protein hDlg [185]. The hDlg protein is a member of the membrane- 
associated guanylate-kinase homologues, which are usually located at cell-cell junctions 
where they appear to have both structural and signaling roles. Phosphorylation of a synthetic 
peptide containing this PDZ-target motif affected protein interaction suggesting 
phosphorylation-dependent PDZ interactions [185]. However, loss of this C-terminal PDZ- 
epitope did not alter PTEN tumor suppressor activity questioning the significance of this 
motif [186].
The C-terminal region contains five potential phosphorylation sites [124]. Transfection 
experiments with several PTEN constructs mutated in the C-terminal region show that these 
mutations interfere with its tumor suppressive function by affecting both stability and 
structure of the protein [186]. This might indicate a regulatory effect of (de)phosphorylation 
on PTEN activity. Therefore, the identification of proteins that are capable of either activating 
or inactivating PTEN through this potential (de)phosphorylation are likely candidates for 
oncogenic mutations. Patients affected by such a mutation might present a CD or a “CD-like” 
phenotype. Based on overlapping clinical features of PJS and CD the recently cloned 
serine/threonine kinase LKB1/STK1 is an interesting candidate for being such a PTEN 
regulator. Both genes are expressed in all tissues examined by northern blot analysis [63]. In 
addition, the expression profiles of PTEN and LKB1/STK1, display a considerable overlap 
during embryonic mouse development, as determined by RNA in situ hybridization [184]. 
However, sequence analysis in CD patients in which no PTEN mutation was present did not 
reveal any mutation in the LKB1/STK1 protein coding sequence (van der Zwaag, unpublished 
results), making it rather unlikely that LKB1/STK1 germline mutations can cause CD. As yet, 
it remains to be seen whether the two proteins function in the same pathway.
PTEN interactors might be protein substrates of PTEN or might play a role in the 
regulation of PTEN activity. In an attempt to identify PTEN interacting proteins we 
performed a yeast two-hybrid screen using the entire human PTEN protein as bait. Both a 
human fetal brain and an adult mouse brain cDNA library were screened. Among the 
identified interactors was ILK, a regulator of integrin and growth-factor signaling. ILK is a 
functional protein kinase depending on PtIns-3,4,5-P3 for its full activation [155]. In addition, 
ILK is capable of phosphorylating PKB/Akt on Ser473, and this modification is essential for 
complete activation of PKB/Akt [155]. A feedback mechanism involving ILK is a potential 
control on PTEN activity, and thereby PtIns-3,4,5-P3 levels. Furthermore, ILK mRNA was
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also detected in the hair follicles, confined to the outer root sheath [187] and 
trichillemmomas, highly specific for CD, derive from this layer. These data indicate that ILK 
is a potential candidate gene to be mutated in CD and possibly involved in regulating PTEN 
activity. However, sequence analysis of the ILK cDNA in CD patients lacking PTEN 
mutations failed to identify mutations in ILK (unpublished results). More important, 
additional experiments failed to demonstrate under more physiological circumstances the 
interaction detected in the yeast two-hybrid system. Nevertheless, it will be interesting to 
determine the activity of ILK in hamartomatous tissue of both PTEN mutated and non-PTEN 
mutated CD patients since PtdIns-3,4,5-P3 levels are likely to affect ILK activity.
There is increasing evidence for involvement of the insulin-like growth factor (IGF-1) in 
central nervous system development (CNS). IGF-1 overexpression in the brain of transgenic 
mice results in postnatal brain overgrowth (up to 85% weight increase), whereas inactivation 
of IGF-1 leads to a decrease in brain size [188]. Furthermore, IGF-1 treatment of cultured 
cerebellar granule cells leads to activation of PI3K, thus resulting in apoptotic resistance [189, 
190]. In Drosophila the same signaling pathway has been implicated in the regulation of cell, 
organ and organism size. Chico mutants (the mammalian homologues of which are the insulin 
receptor substrates IRS1-4) develop into flies 50% smaller than control flies [183]. Loss of 
Dakt1 reduces cell size whereas overexpressing causes increase in cell size [191]. Likewise, 
Drosophila deficient in the p70S6 kinase, a downstream target of Dakt, shows a reduction in 
body size only due to smaller cells [192]. Levels of p70S6 kinase were found to be proportional 
to cell size. Interestingly, disruption of the DPTEN leads to an increase in cell size and cell 
number, while overexpression of DPTEN leads to smaller cells, inhibits cell cycle progression 
and promotes apoptosis [180, 181]. In analogy to these findings one can imagine that in CD 
patients an altered insulin/IGF-1 response might lead to increase in cell size and number 
leading to overgrowth in brain. This suggests that PTEN, by being part of the IGF-1 signaling 
pathway, functions as a “gatekeeper” controlling both the cell size and number in the brain.
The hamartomatous lesions found in CD, which are composed of disorganized cells 
normally present, suggested a possible role for the CD gene in cell adhesion and cell 
spreading. Loss of the wild type PTEN allele has been found in LDD (unpublished results), a 
hamartomatous malformation of the cerebellum, and other hamartomatous lesions indicating 
that complete loss of PTEN activity results in a disturbance of cellular organization and 
allows cancerous outgrowth [193, 194]. It was shown that overexpressing PTEN resulted in a 
reduced cell migration and cell spreading, due to a direct dephosphorylation and inactivation 
of FAK and Shc, and this was accompanied by changes in actin cytoskeletal organization
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[144, 172]. However, conflicting data question whether this finding actually occurs in vivo. In 
Pten-deficient ES cells FAK phosphorylation appeared not different from their normal 
counterpart [168]. A similar finding was reported in PTEN deficient glioma cell line [173]. 
An intriguing alternative to explain a role for PTEN in cell-cell adhesion is the influence of 
PtdIns-3,4,5-P3 levels on ILK activity. The deregulation of ILK activity is a potential 
contributor to oncogenic transformation since overexpression of ILK is known to cause loss 
of cell-cell adhesion (reviewed in [195]). A potential mechanism for this loss of cell adhesion 
is the decrease in E-cadherin expression observed in ILK overexpressing cells. Due to the an 
increase of Lef1, a transcription factor partner of P-catenin, the formation of Lef1-P-catenin 
complex increases which in turn is a negative control of E-cadherin expression. Furthermore, 
ILK has been identified as an activator of PKB/Akt [155] and both are known as inhibitors of 
GSK3, a key player to the degradation of P-catenin. Recently, this deregulation of ILK 
expression due to inactivating mutations in PTEN was demonstrated in PTEN-mutant prostate 
cancer cells [196].
In summary, the identification and isolation of the CD gene PTEN is a perfect illustration 
of the power of molecular genetic tools. Furthermore, mutation analysis identified CD and 
BRR as components of the same entity. PTEN is the first phosphatase identified as a tumor 
suppressor, functioning as an antagonist of PI3K. It is a lipid phosphatase that down regulates 
PtdIns(3,4,5)P3 levels, thereby indirectly inhibiting PH domain-containing proteins of which 
PKB/Akt seems to be the most important. Through this PI3K signaling cascade PTEN inhibits 
cell cycle progression and induces apoptosis. However, still major questions remain to be 
answered. Are there additional downstream components of PTEN signaling? A detailed 
knowledge of these components, including their spatio-temporal characteristics, might explain 
the different phenotypes. Furthermore, how are PTEN activity and expression (upstream 
components) regulated? Loss of those control mechanisms could very well contribute to the 
CD/BRR phenotype and cancerous outgrowth. More directly, modifier genes and genetic 
heterogeneity are issues that need to be examined in greater detail. In view of the high 
mutation rate in cancers a more detailed knowledge on PTEN signal transduction pathways 
might have a direct bearing for studies on multiple cancers and malformation syndromes and 
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Cowden disease (CD) (MIM 158350), or multiple hamartoma syndrome, is a rare 
autosomal dominant familial cancer syndrome with a high risk of breast cancer. Its 
clinical features include a wide array of abnormalities but the main characteristics are 
hamartomas of the skin, breast, thyroid, oral mucosa and intestinal epithelium. The 
pathognomonic hamartomatous features of CD include multiple smooth facial papules, 
acral keratosis and multiple oral papillomas1,2. The pathological hallmark of the facial 
papules are multiple trichilemmomas3. Expression of the disease is variable and 
penetrance of the dermatological lesions is assumed to be virtually complete by the age 
of twenty6. Central nervous system manifestations of CD were emphasized only recently 
and include megalencephaly, epilepsy and dysplastic gangliocytomas of the cerebellum
5 7(Lhermitte-Duclos disease, L D D )' . Early diagnosis is important since female patients 
with CD are at risk of developing breast cancer. Other lesions include benign and 
malignant disease of the thyroid, intestinal polyps and genitourinary abnormalities4,8-10. 
To localize the gene for CD, an autosomal genome scan was performed. A total of 12 
families were examined, resulting in a maximum lod score of 8.92 at 0=0.02 with the 
marker D10S573 located on chromosome 10q22-23.
Twelve families participated in this study, including 40 affected individuals. Since CD has 
clinical manifestations similar to other phakomatoses such as Neurofibromatosis and tuberous 
sclerosis, the initial search for linkage was concentrated on chromosomal regions known to 
contain tumour suppressor genes. We were able to exclude all the candidate loci, among 
which were BRCA1, BRCA2 and the multiple endocrine neoplasia type 2 locus, RET.
Table 1: two-point lod score between the CD locus and CA repeats.
Lod score (chromosome 10q22-23)
locus/0 0.0 0.05 0.10 0.20 0.30 0.40 0 max L o d max
D10S580 -18.33 0.01 0.87 1.11 0.73 0.23 0.17 1.15
D10S605 -5.99 1.80 2.09 1.83 1.14 0.37 0.11 2.11
D10S569 -8.34 0.62 1.15 1.18 0.75 0.23 0.15 1.26
D10S607 -1.34 2.78 2.58 1.85 1.00 0.24 0.04 2.79
D10S219 3.26 7.02 6.41 4.73 2.81 0.96 0.03 7.14
D10S201 -5.96 2.83 2.96 2.42 1.44 0.43 0.09 2.98
D10S573 5.19 8.63 7.77 5.61 3.24 1.03 0.02 8.92
D10S215 4.40 7.99 7.24 5.30 3.09 0.97 0.02 8.19
D10S564 2.34 5.12 4.75 3.56 2.11 0.67 0.04 5.15
D10S583 -4.62 3.59 3.59 2.83 1.72 0.59 0.07 3.65
D10S574 -0.09 4.60 4.37 3.36 2.01 0.63 0.05 4.60
Subsequently, a genome scan was initiated in 5 unrelated Dutch families: N1, N2, N3, N4, 




































figure 1: Pedigrees of three cowden disease families. Haplotypes of persons available for this 
stduy are shown. Bars indicate the chromosome and show regions of crossover. The mutation 
carrying chromosome is depicted in black. Markers used to form this haplotype (proximal­
distal): D10S580, D10S219, D10S573, D10S215, D10S564, D10S583.
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linkage (lod score >1) was obtained at 4 different loci: AMY2B (chromosome 1), D3S1286, 
D10S573 and APOCII (chromosome 19). At two of these loci, the lod score exceeded 2 
(D3S1286 and D10S573). Using additional markers and family 0014, three of these loci could 
be excluded. For the fourth region, located on the long arm of chromosome 10, a statistically 
significant maximum lod score of 6.67 at 0=0.03 was obtained with marker D10S215. A more 
detailed analysis of this region was performed with the inclusion of 7 additional families. 
Eight markers, localized to 10q22-23 (11), showed significant evidence for linkage to CD 
(Table 1). The highest lod scores were obtained with two markers: D10S573, Zmax= +8.92 at 
0=0.02 and D10S215, Zmax= +8.19 at 0=0.02.
Haplotypes were constructed to try and define the most likely position of the Cowden 
gene within this region. The critical recombinants occurred in individuals N4-II-10 and 0014- 
III-3, both whom have features of CD as defined in the Methods section. The most likely 
position of the Cowden gene is in a 5 cM region between D10S215 (N4-II-10) and D10S564 
(0014 III-3) (fig. 1, 2, 3). The pattern of inheritance in all other families is consistent with this 
localization.
Figure 2: Multipoint calculation. Markers used are flanking the Cowden critical region.
In family N2, individual II-11 inherited the unaffected haplotype (fig.1). Based on our 
dermatological criteria, he initially was considered affected. However, his clinical symptoms 
includes a borderline number of keratotic lesions on the forearm and a few non-characteristic
detected which, in contrast, are quite obvious in his affected relatives. Furthermore, both his 







facial papules which were not examined pathologically. No other features of CD could be
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figure 3: Chromosomal localization of the Cowden critical region. Recombinant 0014-II-3 
and N4-II-10 are shown. Hatched circles indicate the affected haplotype, open circles indicate 
the unaffected haplotype. The cowden critical region is depicted as a black bar.
them received the reconstructed unaffected grandmaternal chromosome. If, however, 
individual N2-II-11 is considered affected, the maximum lod score is reduced to 7.14 at 
0=0.04.
There is no indication for genetic heterogeneity among the 12 families who originated 
from four different countries. CD in all the families, among whom are four with LDD, are 
linked to 10q22-23. Although the pathognomonic dermatological features of CD are almost 
invariant, there is large clinical variation among families. An obvious example would be the 
presence or absence of LDD in CD families. The eventual isolation of the gene would resolve 
some of these issues pertaining to genotype-phenotype relationships.
No tumour suppressor gene or oncogene has yet been identified in the Cowden critical 
region. The presence of tumour suppressor genes on chromosome 10 has been indicated by 
loss of heterozygosity (LOH) in different types of tumours. Studies in follicular thyroid and 
uterine tumours, all components of CD, have shown frequent LOH on 10q (ref. 12,13). The 
region of LOH was determined with more detail in endometrial tumours and the Cowden 
critical region may partially overlap this region14.
There are several known genes mapped to regions overlapping 10q22-23: ACTA2, Gludl, 
INFI56 and ZNF32 (GDB). Apart from ZNF32, the genes mentioned are not strong 
candidate genes. ZNF32 is a member of the family ZNF KOX genes which encode the C2H2 
Krüppel type (Class I) of zinc finger proteins15. There are at least two examples of inherited
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syndromes with developmental defects which are known to result from germline mutations in 
ZNF genes. The first is GLI3 in Greig cephalopolydactyly syndrome16 and the second is the
17 18WTl tumour suppressor gene in Denys-Drash syndrome ’ . In addition, other ZNF-type 
proteins can bind DNA at promoter sites and probably play important roles in gene
19 23regulation . Fine mapping of the ZNF32 is necessary to determine if it maps within the 
Cowden critical region.
The two most severe complications for CD are neurological and neoplastic. There is 
insufficient information whether megalencephaly is caused by hypermyelination or by 
increased cerebral cellularity. Both hypermyelination and hypercellulairity are features 
consistent with the possibility that the Cowden gene might be a tumour suppressor gene. 
From an oncologic point of view, we suspect the CD gene might play a role in both familial 
and sporadic breast cancer and in familial thyroid syndromes. The high frequency of breast 
cancer in female Cowden patients (30%)4,8-10 makes it a strong candidate gene for a new 
breast cancer susceptibility gene. In addition, its candidacy for the locus of non-medullary 
thyroid cancer should be considered.
In the meantime, however, DNA-based predictive testing for CD in informative families is 




Families N1, N2, N4, N5, 0014 and family D have been described before 4,5,7,24 Fam. N3 
was ascertained because the proband was diagnosed on clinical grounds to have LDD. The 
neurological and oncologic features of these families will be reported elsewhere in detail 
(Peeters et al., Lin et al., in preparation). In addition, family D was ascertained because of 
LDD in the proband’s grandfather . For the linkage studies we used the operational criteria 
formulated by the international CD consortium.
Criteria for the diagnosis of CD used by the International Cowden Consortium
Pathognomonic criteria for the diagnosis of Cowden disease include facial 
trichilemmomas, acral keratoses, papillomatous lesions and mucosal lesions. Breast cancer, 
thyroid cancer (esp. PTC type), macrocephaly (97%ile) and LDD were considered major 
criteria. Thyroid lesions (goitre), mental retardation (IQ<75), gastrointestinal hamartomas,
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fybrocystic disease of the breast, lipomas, fibromas and genitourinary tumours or 
malformations were applied as minor criteria. For the diagnosis of an individual the 
mucocutanous lesions are diagnostic if there are 6 or more papules, of wich 3 or more must be 
trichillemmomas. Also cutaneous facial papules and oral mucosal papillomatosis, or oral 
mucosal papillomatosis and acral keratosis, or palmo plantar keratosis (6 or more) is 
considered diagnostic for CD. Two major criteria of wich one is either LDD or macrocephaly, 
1 major with 3 minor criteria or 4 minor criteria are indicative for CD. All patients fulfill 
these criteria.
Typing of DNA markers
25Genomic DNA used for the typing of the DNA polymorphisms was isolated as described25. 
Amplification of the polymorphic regions and the separations of the amplified fragments was
performed as described26,27.
Statistical evaluation
28Lod scores were calculated using the Linkage program (version 5.1) subroutine Mlink for 
the two-point linkage. Multipoint calculations were done using the FASTLINK program
29(version 2.30), subroutine linkmap . The gene frequency was estimated as 0.000001. Non­
penetrance after the age of twenty was estimated to be 10%. Individuals above the age of 
twenty were typed and used for lod score calculation. For the individual N2-II-11, the 
affection status was said to be unknown.
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Abstract
Cowden disease, also known as multiple hamartoma syndrome, is an autosomal dominant 
cancer syndrome with a high risk of breast and thyroid cancer. The gene involved has been 
localized to chromosome 10q22-23. Recently, the tumour suppressor gene PTEN/MMACl, 
encoding a putative protein tyrosine or dual-specificity phosphatase, was cloned from that 
region and three mutations were detected in patients with Cowden disease. We confirmed that 
the PTEN/MMACl gene is indeed the gene for Cowden disease by a refined localization of 
the gene to the interval between D10S1761 and D10S541, which contains the PTEN/MMACl 
gene and by mutation analysis in eight unrelated familial and 11 sporadic patients with 
Cowden disease. Eight different mutations were detected in various regions of the 
PTEN/MMAC1 gene. One mutation was detected twice. All detected changes in the gene can 
be predicted to have a very deleterious effect on the putative protein. Five of the nine patients 
have a mutation in exon 5 coding for the putative active site and flanking amino acids. 
Evaluation of the clinical data of the patients in which a mutation could be detected gives no 
clear indications for a correlation between the genotype and phenotype. In 10 patients no 
mutation could be detected so far. In support of the linkage data, no evidence has emerged 
from the phenotype of these patients suggestive for genetic heterogeneity.
Introduction
Cowden disease (CD) (MIM 158350), also known as multiple hamartoma syndrome, is a 
rare familial cancer disease named after the first patient described in 1963 (1). The disease is 
inherited in an autosomal dominant pattern. Characteristic for CD are oral and facial papules 
together with hamartomatous features of the thyroid, breast and digestive tract (1,2). Multiple 
trichilemmomas are considered to be the pathological hallmark of the disease (3). CD patients 
have a predisposition to develop both benign and malignant neoplasms. Female patients have 
a high risk of developing fibrocystic disease and carcinomas of the breast; also goiter, 
adenomas and follicular cell carcinomas of the thyroid gland and polyps of the digestive tract 
are part of the disease (4-7).
Apart from the CD manifestations described above a variety of neurological symptoms 
can be found. Lhermitte-Duclos disease (LDD), or dysplastic gangliocytoma of the 
cerebellum is, together with megalencephaly, the most important central nervous system
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manifestation (8). Other neurological signs range from tremor and ataxia to epilepsy and 
mental retardation (8-10, reviewed in 11).
Recently, in an extensive linkage study in 12 CD families, we localized the gene for CD to 
10q22-23 between the markers D10S215 and D10S564 (12). There were no indications for 
genetic heterogeneity. The recently cloned tumour suppressor gene PTEN/MMAC1, encoding 
a putative tyrosine or dual-specificity phosphatase (13,14), was suggested to be involved in 
CD (15). We confirmed that the gene is involved in CD by refinement of the linkage data and 
mutation analysis in the PTEN/MMAC1 gene in eight familial and 11 sporadic CD patients. 
We identified eight different mutations in nine patients.
Results
Fine Mapping
Figure 1. Refinement of the localization of the gene for CD; key recombinations. Black 
circles indicate the affected haplotype, open circles the unaffected haplotype and grey circles 
uninformativity. The Cowden critical region is depicted as a black bar. Markers which were 
used in the linkage analysis described in (12) are given in bold. The location of the 
PTEN/MMAC1 gene is marked by an arrow. The haplotypes of two healthy sibs from the CD 
families N4 and N5, who both have macrocephaly, are depicted on the right.
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Nineteen CA-repeat markers spanning the 10q22-23 region were tested in the families N1- 
N5 (12) and revealed that the Cowden critical region is between D10S1761 and D10S541 
(Fig. 1). In the primary linkage study individual N4-II-10, determining the proximal border of 
the critical region, was considered to be affected (12) although his clinical status was 
disputed. He was known to have hyperkeratotic papules, macrocephaly and mild ataxia. 
Recently, clinical re-examination was carried out by an independent clinician leading to the 
conclusion that he is unaffected. Apart from macrocephaly and mild unsteadiness, he has two 
hyperkeratotic papules on his forearm and a naevus naevocellularis on his scalp. His skin 
abnormalities only do not fulfil the criteria for diagnosis of CD (12) and macrocephaly in 
itself does not justify the diagnosis of CD. Surgical treatment for cervical disc disease and a 
period of alcohol abuse might explain his mild unsteadiness. The haplotype in combination 
with the diagnosis of this individual are in accordance of PTEN/MMAC1 being the Cowden 
gene (Fig. 1).
Mutation analysis of the PTEN/M M AC1  gene
Mutation analysis of the PTEN/MMAC1 gene was performed using lymphocyte DNA of 
eight familial and 11 sporadic CD patients. The nine described exons of the gene were 
amplified and sequenced. In two families (N2 and N4) and seven sporadic patients a 
heterozygous mutation was detected. The mutations are listed in Table 1. We identified 
missense, nonsense, frameshift and splice site mutations.
Patient Control
Figure 2: Excerpt of the sequence of exon 
5 using the radioactively labeled reversed 
primer. The heterozygous transversion of G 
to A in a patient of family N2 is marked by 
an asterix. The substitution is predicted to 




Table 1: Summary of the clinical data of the patients and description of the mutations
Patient Sex Skin Age Thyroid Breast Intestine Urogenital LDD neurologi­
cal signs
Head mutation and 
predicted affect






+ nm Insertion o f  TTAC 
(exon 2,nucleotide 
1192/1193; frameshift, 
aa insertion premature 
stop in codon 63)












+(1) +(5) m ac(2 )
meg
(3)
GT to TT (intron 4, 
splice site mutation
n40 m + 57 goitre n.r. n.d. n.d. - + mac CAC to CGC: 
H isi23Arg (exon 5)
n130 f + 42 adenoma - - n.d. - - mac TGT to CGT: 
Cys124Arg (exon 5)




(3) myomatosis nm(1) Arg130Stop (exon 5)
n264 f + 38 goitre fibrocystic
disease
fibroadenomas
n.d. n.d. + meg CGA to TGA: 
Arg130Stop (exon 5)
n275 m + 46 - n.r. polyps n.d. + + mac GAA to TAA: 
Glu157Stop (exon 5)
n342 m + 47 goitre n.r. polyps kidney
cysts
+ mac Insertion o f  A in codon 
183 (exon 6) 
frameshift, premature 
stop in codon 189
n269 m + 33 n.r. n.d. n.d. + + mac Deletion o f  GA in N 262 
(exon 7) frameshift 
premature stop
For the families the number of patients with a specific symptom are given between brackets. f, female; F, 
familial; LDD, Lhermitte-Duclos disease; m, male; mac, macrocephaly; meg, megalencephaly diagnosed by 
MRI scanning; n.d., no signs but not examined; nm, normal; n.r., not relevant; +, present; - ,  absent; Skin 
abnormalities include trichilemmomas, lichenoid and verrucous papules on the face, oral mucosal papilomatosis, 
hyperkeratotic lesion on the distal extremities, and punctate keratosis on the palms and soles. Neurological signs 
include tremor, clumsiness, incoordination, hearing defects, epilepsy and dizzyness.
There are three different mutations in the active site sequence motif HCxxGxxRS/T of 
protein tyrosine phosphatases and dual specificity phosphatases (16,17). Two of these 
mutations are missense mutations, His123Arg and Cys124Arg, and one is a nonsense 
mutation Arg130Stop, which occurred twice (Fig. 2). All three can be predicted to lead to a 
complete or severe loss of phophatase activity (17). By sequencing the A-lane with the 
reversed primer, the Arg130Stop mutation was shown to cosegregate with CD in family N2 
(Fig. 3). A second nonsense mutation Glu157Stop was detected in the sequences flanking the 
active site and therefore can be expected to reduce the phosphatase activity.
In family N4 the first nucleotide of intron 4 was changed from G into T causing a mutation 
in the nearly invariant splice site sequence GU to UU. This will lead either to exon skipping 
or to insertion of intron 4 into the transcript. The mutation was shown to completely 
cosegregate with CD in the family by sequencing of the T-lane.
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The three remaining mutations lead to a frameshift and premature termination of the 
protein at codons 63, 189 and 297 which are the eighth, sixth and 36th codon after the 
frameshift mutation, respectively. Also these mutations can be predicted to be very 
deleterious to the protein. Mutations were confirmed in independently amplified PCR 
fragments. To exclude common polymorphisms, 50 controls were tested in whom none of the 
mutations were found.
family N2
Figure 3: Analysis of the segregation of the Arg130Stop mutation in family N2. Sequencing 
of the A-lane was performed using the radioactively labeled reversed primer of exon 5.
Discussion
We have refined the localization of the CD gene and performed mutation analysis in the 
PTEN/MMAC1 gene thereby confirming that this gene is causative of CD (15). A mutation 
was detected in nine patients, two of whom are familial (N2 and N4). Five of these mutations 
are in exon 5 in addition to three of four described by Liaw et al. (15). This suggests that exon 
5 (amino acids 86-165), coding for the active site and flanking amino acids, is a ‘hotspot’ for 
mutations in patients with CD. So far, missense mutations are only found in the active site. 
The Arg130Stop mutation was detected twice in our patient group and once in a glioma (14) 
and is caused by a mutation in a CG dinucleotide. Since these are known to have a relatively 
high mutation frequency, the CG in codon 130 might be prone to become mutated. In 10 
patients no mutation was found. Three of these patients are from families linked to 10q22-23 
(12). CD in these individuals might be due to a change in the promoter sequences, deletion of
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an entire exon which remains undetected with the method used, or a mutation in an intron 
leading to aberrant splicing. In support of the linkage data, no evidence has emerged from the 
phenotype of these 10 patients suggestive for genetic heterogeneity.
Since different types of mutations were detected in several regions of the gene, we made an 
attempt to correlate symptoms and specific mutations. Skin abnormalities including 
trichilemmomas were detected in patients with all types of mutations but not in patient n331 
although trichilemmomas are pathognomonic for CD (3). Patient n331 testifies to the 
observation in families with CD that the skin abnormalities are not fully penetrant (4). The 
combination of oncological features including LDD justifies in our opinion the diagnosis of 
CD. At the same time it raises the question which and how many non-dermatological criteria 
allow the clinical diagnosis. The detection of a mutation in this patient indicates that the 
PTEN/MMAC1 gene is a good candidate for familial cancer disorders with (a combination of) 
neoplasms associated with CD, for example familial breast cancer and/or thyroid cancer, in 
the absence of skin abnormalities.
Involvement of the thyroid was found in the majority of patients with the exception of 
patient n275 with the Glu157Stop mutation and patient n269 with a frameshift mutation in 
exon 7. Patient D described by Liaw and co-workers (15) also has the Glu157Stop mutation 
and no thyroid symptoms too, suggesting that this is specific for this mutation. A larger 
number of patients is necessary to confirm a phenotype-genotype correlation for thyroid 
symptoms in CD.
Breast abnormalities are found only in females with the exception of one male patient. So 
far, all affected females have a mutation in the N-terminal half of the protein. Within this 
group of females, there are no indications for specific mutations leading to breast 
involvement. Also for intestinal polyps, urogenital involvement and neurological signs, there 
are no indications for phenotype-genotype correlations.
LDD is associated with mutations leading to a premature termination of the prot ein and a 
splice site mutation but not with the detected missense mutations. This is also true for the 
patients described by Liaw et al. (15). We cannot confirm their suggestion that LDD is 
associated with the more N-terminal truncations since patient n269 has a frameshift mutation 
in codon 262. However, one could argue that the long stretch of 35 changed amino acids 
between the frameshift and the termination might have a more deteriorating effect on the 
protein in comparison to the described Arg233 nonsense mutation which is not associated 
with LDD (15).
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The identification of the gene involved in CD makes early, presymptomatic diagnosis of 
the disorder possible not only in the familial cases but also in the large fraction of sporadic 
cases in whom diagnosis based on linkage analysis cannot be performed. This is of great 
clinical importance since accurate surveillance for the occurrence of neoplasms associated 
with CD can be offered now to the carriers. Our study underlines difficulties in the diagnosis 
of CD based on clinical symptoms since we had two sibs from CD families suspected for the 
disorder because of macrocephaly: N4-II-10, who has been described in the results section, 
and a 5 year old girl (N5-IV-1, Fig. 1) with macrocephaly and a haemangioma on her ankle 
occurring regularly in CD. Both individuals did not have the affected haplotype in the interval 
of the PTEN/MMAC1 gene (Fig. 1) and for N4-II-10 we could show the absence of the 
mutation cosegregating with the disorder in the family. The mutation in family N5 has not yet 
been detected. These results indicate that in families, macrocephaly as an early indication for 
CD has to be treated with caution. In the Dutch families N1-N5, macrocephaly is present in 
24 of 25 patients but also in five of 12 unaffecteds (E.A.J. Peeters, in preparation).
Mutations in the PTEN/MMAC1 gene causing CD can give some clues as to the function of 
the gene. The presence of megalencephaly, and the occasional hypertrophy of breasts and 
increased size of hands and feet in patients with CD (18,19) suggest that haploinsufficiency of 
the gene leads to disturbance of growth restriction in development. Furthermore, as already 
suggested by Liaw et al. (15), inactivation of the second allele causes disorganization and 
proliferation resulting in hamartomas, the hallmark of CD. Somatic mutations in other tumour 
suppressor genes or oncogenes could then cause malignant transformation. The rare 
occurrence of glioblastoma multiforme in CD patients supports the notion that the appearance 
of this tumour is the result of a cascade of events in which a mutation in the PTEN/MMAC1 
gene probably is the last step. Furthermore, the putative nature of the gene i.e. a protein 
tyrosine or dual specificity phosphatase is in agreement with the observed features of CD: 
these phosphatases are involved in cell proliferation and cell differentiation (17). The 
occurrence of acquired mutations in the PTEN/MMAC1 gene in a number of tumour types 
(13,14) and the germline mutations causing the rare CD makes this gene comparable to p53 
showing mutations in many tumour types and in the rare Li-Fraumeni syndrome, promising 
interesting future results on the PTEN/MMAC1 gene.
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Materials And Methods 
Patients
Diagnoses of patients were based on dermatological criteria with the exception of patient 
n331 (see Table 1). In this patient diagnosis was based on the oncological features and LDD. 
Fine-mapping was performed in the families N1-N5. The families N1 and N2 have been 
described by Starink et al. (4) and the families N4 and N5 by Padberg et al. (8). Patient n275 
is described by Lindboe et al. (20). Clinical features of patients in which a mutation was 
detected are summarized in Table 1.
Typing of CA repeat markers
Genomic DNA used for the typing of the DNA polymorphisms was isolated as reported 
before (21). Amplification and separation of the polymorphic CA-repeat fragments were 
performed as described (22). The markers and their order were as given by Genethon (23) 
with the exception of D10S1761 and D10S532 which are ordered according to recombinations 
in our families.
Mutation analysis
For mutation analysis, DNA fragments containing the exons were amplified using the inner 
primers described in (14). PCR products were purified from the reaction mixtures using 
QIAquick spin colums (Qiagen) according to the gel extraction protocol. The fragments were 
sequenced using the ds cycle-sequencing system (Gibco-BRL) following the manufacturer’s 
protocol.
Analysis of control individuals
The presence of the detected mutations in 50 unrelated and unaffected individuals was 
tested in lymphocyte DNA isolated as described (21). For the mutations in the exons 4, 5 and
6, oligonucleotides of 14-16 bp were developed with approximately in the middle either the 
wildtype or mutated nucleotide. Exons were amplified as described and blotted onto 
GeneScreen Plus. Ten nanograms of the oligonucleotides were radioactively labeled and used
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for hybridization in 5X SSPE (0.15 M NaCl, 10 mM N H 2PO4 , 10 mM EDTA, pH 7.4),
0 .3 .  SDS at 37°C for at least 6h. After hybridization blots were washed in 5xSSPE, 0.3% 
SDS for 15 min at room temperature and 2-5 min at 37°C. The insertions in exons 2 and 7 
were tested as length polymorphisms by amplifying the exons as described and separating 
them as described for the CA repeat markers (22).
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Abstract
Cowden disease (CD) is characterized by multiple hamartomas in a variety of tissues. The 
pathological hallmark is the presence of a number of trichilemmomas. Several neurological 
symptoms are also part of CD with megalencephaly and Lhermitte-Duclos disease (LDD) as 
the most important features. Early recognition of CD patients is important because of the 
increased risk to develop malignancies. Breast cancer is the most frequent malignancy, but 
also urogenital, digestive tract, and thyroid cancers are found with higher frequencies. CD 
was localized to chromosome 10q23 and the PTEN gene (also known as MMAC1 or TEP1) 
was shown to be involved. Germline mutations were identified in both familial and sporadic 
CD patients. We identified eight PTEN mutations, of which seven were novel, in 13 CD 
patients. Combined with previous data we have identified 17 independent CD mutations. 
Gross DNA alterations in CD patients were not detected. Genotype-phenotype relations are 
discussed. The only correlation suggested to exist is that missense mutations are not detected 
in LDD patients. However, larger numbers are needed to confirm this. Association of PTEN 
mutations and the occurrence of malignant breast disease found in an earlier study can not be 
confirmed. Clinical features of five CD patients without a PTEN mutation in the coding 
sequence do not differ from CD patients with a PTEN mutation. Furthermore, it is likely that 
we have identified the majority of CD patients in the Netherlands. From this we estimate that 
CD has a prevalence of about 1 in 250,000 in the Dutch population with a low mutation 
frequency.
Introduction
Cowden disease (CD, MIM #158350) is a hereditary autosomal dominant cancer syndrome
1 2with a marked variable expression, between and even within families ’ . The main 
characteristic of this disorder is the formation of hamartomas in a variety of tissues. The
3 5majority of the patients (~90%) develop characteristic skin and mucocutaneous lesions - . 
Multiple trichilemmomas, benign neoplasms of the hair follicle, are considered to be 
pathognomonic for this disease6. Other typical features include oral and facial papules, goiter 
and benign hamartomas of the thyroid and digestive tract . A large number of CD patients 
(i.e. more than 80%) develop macrocephaly , which is a true megalencephaly, but only a 
fraction of the patients develop Lhermitte-Duclos disease (LDD). This rare condition is 
believed to be a hamartomatous outgrowth of the cerebellum, characterized by hypertrophic
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8 9ganglion cells. LDD was only recently identified to be part of CD ’ . Megalencephaly and
LDD are the most important neurological features of CD and the cause of symptoms like
8 10tremor, ataxia, and mental retardation " . In addition to these benign symptoms, CD patients 
have an increased risk to develop malignancies. They include follicular cell carcinoma of the 
thyroid, carcinomas of the breast and malignant cancers of the urogenital and digestive tract. 
The highest risk is noted for breast cancer in females, approximately 70%11.
We assigned the gene responsible for CD to chromosome 10q23 by an extensive linkage
12study in 12 families . The gene encoding PTEN (alternatively named MMAC1 or TEP1), a
13 15dual specificity phosphatase identified within the critical region , was shown to be 
involved by the identification of germline mutations present in a number of CD patients16,17.
Germline mutations were also identified in two other distinct but related syndromes,
18 21Bannayan-Riley-Ruvalcaba syndrome (BRR) and Juvenile Polyposis Syndrome (JPS) " . 
Symptoms found in BRR and CD are partly overlapping and comprise macrocephaly, 
intestinal hamartomatous polyps, lipomas and heamangiomas. The R233X mutation in the 
PTEN gene has been found in both a CD and a BRR patient19. This suggests that CD and 
BRR represent a variable spectrum of the same disorder. Alternatively, modifier genes might 
be responsible for the different phenotypes occurring in patients with an identical mutation. In 
JPS, characterized by hamartomatous polyps throughout the digestive tract and predisposition
to digestive tract cancer, mutations have been identified which are so far not described for CD
21or BRR patients . Genetic heterogeneity for JPS was suggested by a linkage study performed 
in 8 informative JPS families. Linkage with the PTEN gene was excluded in these 8 families
and also mutation analysis of the coding region of the PTEN gene did not reveal any sequence
22alterations . Recently it was shown that the SMAD4 gene is the major gene involved in 
familial JPS 23.
The identification of PTEN as a tumor suppressor has created a great deal of interest in the 
field of cancer research. Studies have shown the involvement of PTEN in a large number of 
sporadic tumors. Mutations have been identified in glioblastomas, prostate cancer, 
melanomas, thyroid and endometrial tumors13,14,24-26. In some of these cancers, e.g. 
glioblastomas, melanomas and prostate cancer, PTEN mutations seem to be associated with
24,27,28tumor progression ’ ’ . In endometrial carcinomas PTEN turned out to be the most
frequently mutated gene so far26,29. Recent studies suggest that at least part of the function of
30PTEN is the regulation of cell migration and interactions with the extracellular matrix .
Here we describe a detailed mutation analysis of the coding sequence of the PTEN gene in 
CD families and sporadic CD patients. We identified mutations in eight unrelated CD
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patients. One mutation was detected previously. Genotype-phenotype correlations are
17discussed for these 8 mutations and 9 mutations described previously .
Material And Methods 
Patients
In total, thirteen patients were included in the mutation analysis, seven families and six 
sporadic patients. Dutch CD patients, both familial and sporadic, were diagnosed mainly on 
the presence of the dermatological lesions2,6. Family anamnesis of the six sporadic patients
were suspect in three cases. Parents of these patients were not examined for clinical signs. All
12patients fulfill the criteria of the international Cowden Consortium . Phenotypes of the CD 
patients and CD families with a PTEN mutation can be found in Table 1. Of all patients 
combined, eight patients were diagnosed with LDD, four of which are familial. The five CD 
cases in which no PTEN mutation was detected were ascertained because of the presence of 
multiple features seen in CD. Family N1 has been used in the original linkage study and was 
previously described by Starink et al . Trichilemmomas, macrocephaly, and goitre were 
present in the proband analysed in CD family N9. The proband’s mother died because of a 
thyroid carcinoma. Also, her brother has clinical symptoms of CD. Patient 5899 has an 
extensive clinical history, including oral papillomatosis, goitre, endometrium carcinoma, and 
breast cancer. Patient n354 was ascertained because of the presence of skin lesions, goitre, 
and mamma-carcinoma. Family anamnesis of both patients was suspect. The fifth patient 
(n1420) has skin lesions although no trichilemmomas were detected on pathological 
examination. Furthermore, this patient has macrocephaly and is known to have epileptic 
seizures. Family anamnesis was negative.
Mutation Analysis
Sequence analysis was performed on PCR products, using intronic primers designed to 
amplify the nine different exons and the corresponding exon/intron boundaries of the PTEN
13gene . Genomic DNA of patients was isolated using standard procedures. Products were gel 
purified using a PCR purification kit (Qiagen). Cycle sequencing was performed in the 9600
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Patient Sex Skin Thyroid Breast I UG LDD Head Neurol. signs Mutation
N6(F) 3f n.e. I33del, exon 2 NT
n331 f 159insTTAC, exon 2
N3 (F) 2m/1f IVS3+1G>C, intron 3
N4 (F) 3m/2f n.e. IVS4+1G>T, intron 4
ddW f n.e. IVS4+1G>T intron 4
dd14443 f Q97X, exon5
n40 m n.e. n.e. H123R, exon 5 NT
n130 f n.e. C124R, exon 5 NT
N2 (F) 2m/7f R130X, exon 5
n264 f n.e. n.e. R130X, exon 5
n275 m n.e. E157X, exon 5
n342 m 545insA, exon 6
N8 (F) 3f n.e. G165E, exon 6 NT
n269 m n.e. n.e. 783delGA, exon 7
N5(F) 1m/6f IVS7+1G>T, intron 7
N7 (F) 6m/3f 937delA, exon 8
WvL L320X, exon 8
Table 1: CD-mutations and their phenotype.(F),familial; I, Intestine; UG, urogenital; m, male; f, female; n.d., not examined; white bar, normal; gray bar, 
benign lesions present or (skin) trichilemmomas and/or oral papilomatosis or (head) macrocephaly; black box, malignancies; NT, non truncating;
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Thermal Cycler (ABI) with the dRhodamine dye terminator kit (ABI) for 28 cycles consisting 
of 10 sec at 96°C, 5 sec at 50°C and 4 min. at 60°C. Sequencing products were precipitated 
with 70% ethanol, 0.5 mM MgCl2 and resuspended in 2.5 |il loading buffer. The samples 
(2^l) were run and analyzed on an ABI 377 automated sequencer.
A PTEN cDNA probe, encompassing the complete coding sequence and part of the 3’ and 
5’ UTR, was used to screen for the presence of gross DNA alterations in patients without an 
identified mutation. DNA (7 |ig) was digested with HinDIII and PstI, blotted to 
GenescreenPlus and hybridized with the PTEN cDNA probe. As a control probe PMP22 
cDNA (17p11.2-p12) was used.
Control Analysis
Identified mutations were confirmed in independently amplified PCR products. Each 
mutation was checked for its presence in the normal population by allele-specific 
oligonucleotide hybridization. The appropriate exon was amplified in 50 unrelated unaffected 
individuals using genomic DNA. Allele-specific oligonucleotides of 14-16 bp were 
synthesized containing either the wildtype or the mutant sequence. PCR products were dot- 
blotted onto GenescreenPlus. The oligonucleotides were labeled radioactively and hybridized 
in 5xSSPE / 0.3% SDS at 30°C overnight. Blots were washed in 5xSSPE / 0.3% SDS at the 
proper temperature. Insertions and small deletions were tested as length polymorphisms by
32amplifying the exons in the presence of I-( P)dCTP and separating them on a 6.6% 
denaturing acrylamide gel.
Results
We have screened 13 patients diagnosed with CD for mutations in the coding region of the 
PTEN gene and eight mutations were identified (Table 2). All mutations were heterozygously 
present in genomic DNA. One mutation was detected previously. The patient group consists 
of 6 sporadic cases and 7 familial cases for which the corresponding families were linked to 
10q23. The mutations included two small deletions located in exon 2 and 8. Three splice site 
mutations were located in intron 3, 4, and 7. One missense mutation was found in exon 6. 
Two nonsense mutations were detected, one in exon 5 and the second in exon 8. All mutations 
identified in CD families were shown to cosegregate with the disorder. None of the detected
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mutations were present in 50 controls, excluding common polymorphisms, and all mutations 
were confirmed in indepently amplified PCR fragments.
In three sporadic and two familial CD patients we did not identify a mutation. We were 
only able to analyze the PTEN gene in four of these patients for any gross alterations. 
Genomic DNA, digested with HinDIII and PstI, was hybridized with a PTEN cDNA probe. 
This probe contained the entire coding sequence and a small portion of the 3’ and 5’ UTR. 
There were no indications for any gross alterations in the PTEN gene of these four patients.
Table 2: Description of the identified CD mutations with their predicted effect.
Patient Mutation predicted effect
N6(F) 97-99delATT I33del
N3 (F) IVS3+1G^C splice-site mutation
ddW IVS4+1G^T splice-site mutation
dd14443 289C>T Q97X
N8 (F) 494G>A G165E
N5(F) IVS7+1G^T splice-site mutation




Cowden disease is an autosomal dominant cancer syndrome, caused by mutations in the 
recently cloned tumor suppressor gene PTEN, located at 10q23.112,16,17. In this study we have 
performed an extensive mutation analysis in 13 unrelated patients, in which we detected 8
17mutations. Combined with our previous data we have identified 17 mutations (Fig. 1) in 22 
patients. Two mutations were detected twice in our patient group. Mutations included 
missense (18%), nonsense (29%) and splice-site mutations (24%), small insertions (12%) and 
deletions (18%). The mutations were dispersed throughout the gene with a clustering in exon
5. The mutations and a summary of clinical data are presented in Table 1.
In total, we identified in seven of the nine familial CD cases a PTEN mutation. Family N1,
in which we did not find a mutation, has been used in the original linkage study and the data
12are compatible with linkage to 10q23 . However, since the size of this family is small the 
data are not statistically significant. Clinical symptoms include skin lesions, macrocephaly, 
mama-carcinoma and goitre. Recently, three papers described the presence of a processed
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31 33pseudogene or homologue PTH2 , located on chromosome 9. To exclude involvement of 
PTH2 in this family we tested markers, including D9S165, D9S1878 and D9S15. These 
markers flank the interval containing this gene. Haplotype analysis indicated that the PTH2 
locus is not linked to CD in this family (data not shown). So far, only the coding region of the 
PTEN gene is analyzed for mutations and gross alterations are excluded. Mutations in the 5’ 
regulatory regions, other regions that influence proper PTEN functioning or intronic 
mutations that create alternative splice-sites might be present in this family. The second 
family (N9) without a detected mutation in PTEN does show the typical skin lesions, 
confirmed by pathological examination. Also, goitre and macrocephaly are present. The 
probands mother died of a metastasized thyroid carcinoma. We performed mutation analysis 
in the proband and are now collecting blood samples of other family members to either prove 
or exclude involvement of the PTEN gene.
In 10 of the 13 sporadic patients a mutation in the PTEN gene was detected. The three 
patients in which no PTEN mutation was detected had typical features of CD. These cases 
might have mutations in the same, not yet analyzed, regions of the gene as mentioned above. 
Such mutations are not detectable by the methods used in this study. Another explanation for 
not finding mutations in both these sporadic and familial patients is genetic heterogeneity, 
suggested by the existence of CD families not linked to 10q23.134 We also tested patients, 
offered to us for DNA-diagnosis, with features commonly seen in CD but without the 
pathognomonic skin lesions. So far, we did not detect a mutation or a gross DNA alteration in 
any of these patients. The absence of mutations in this set of patients might underline the 
importance of skin lesions in CD diagnosis.
All but four mutations detected so far result in a premature truncation of the protein. This 
large proportion of protein truncating mutations is in agreement with the mutations described
20 35 36in the literature ’ ’ . Of the four mutations that do not result in a protein truncation, three are 
missense mutations and one is an in-frame 3 bp deletion. Two missense mutations result in a 
substitution of 2 invariant amino acids in the active site, His123 and Cys124, by an Arginine. 
A dramatic decrease of phosphatase activity was shown for a His123Tyr substitution in the
37active site and one might expect that this is also true for these two missense mutations. The 
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Figure 1: Shown are the locations of the alterations detected in the PTEN gene in relation to 
the functional domains of the protein. Corresponding phenotypes are depicted in table 2. The 
N-terminal part of PTEN is homologous to other phosphatases and also to tensin and auxilin. 
The C-terminal part of PTEN shares no homology with other proteins but contains three 
putative tyrosine (Y) and two putative serine phosphorylation (S) sites and a PDZ binding 
domain at the 3’end of the protein
This mutation is localized in a structural element, an I-helix, conserved between PTEN and
38tensin. Therefore, this mutation is predicted to disrupt the PTEN activity . The mutation is 
located at the second nucleotide in exon 6 at the splice acceptor site. However, it is unlikely 
that this mutation has a dramatic effect on RNA splicing since the second nucleotide of an
39exon is not part of the consensus sequence of the 3’ splice site . The 3 bp in-frame deletion 
(Ile33) does not result in protein truncation. Codon 33, however, is conserved in both tensin
and auxilin. This mutation might affect interactions with other important molecules or the
20mutation might alter the stability of the RNA as is suggested by Lynch et al .
The families and sporadic patients were considered for possible genotype-phenotype 
correlations. CD patients show involvement of multiple organ sites and all sites are involved 
in mutations throughout the protein. No specific mutation or part of the protein seems to be 
connected with a particular phenotype. We cannot exclude that there is a genotype-phenotype 
correlation for specific mutations. However, because only very few mutations are detected in 
more than one case a statistical analysis was not performed. Also, from family data we know 
that there is a marked variation in expression and age of occurrence of the various symptoms.
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This is in agreement with PTEN functioning as a tumor suppressor gene, as a second hit 
randomly occurs in different tissues. LDD, however, is not seen in patients with a missense
35mutation (8 cases). This is also true for the three LDD cases described in the literature . It is 
also notable that so far patients with mutations in exon 1, 8 and 9 are not diagnosed with
20 35LDD ’ . Furthermore, the two mutations found in exon 2 do not result in the typical 
papillary skin lesions. Only one of the three patients in family N6 has oral papillomatosis. A 
larger number of patients is needed to confirm any of these associations. We can not confirm 
the observed association between the presence of a PTEN mutation and malignant breast
35disease . Four of the five female CD patients, of which two are mother and daughter, without 
a detected PTEN mutation do show malignancies of the breast. Furthermore, a brother of one 
of these female CD patients developed bilateral breast cancer. This is in contrast to the data 
reported in the literature, in which only one out of seven patients with no detected PTEN
35mutation had malignant breast disease . This indicates that larger numbers are needed to 
address these clinically relevant observations.
We have used the PALGA database, the Dutch Network and database for Pathology, to 
screen for any unknown CD patients. This network contains information of more than 4.5 
million individuals. In total, we have identified 45 CD patients in the age group of 25 years 
and older in the Dutch population, including patients not participating in this study. It is likely 
that we have identified the majority of patients in the Netherlands in this way. However, we 
can not exclude possible misdiagnosis of CD patients. Although CD can be expressed with 
great variation, even within families, mutation analysis of both breast cancer patients and 
families indicates that the CD symptoms are highly expressed and well recognized by 
clinicians. Not or rarely a PTEN mutation is identified in these breast cancer cases40,41. 
Furthermore, CD can be contributed to a PTEN mutation in the majority of the CD patients. 
Therefore, we estimate that the prevalence of CD is between 1 in 200,000 and 1 in 250,000 in 
the Dutch population. In four patients it is likely that CD is caused by a new mutation. Three 
of the four cases are proven “de novo” mutations. In two patients (n269, n40) the expected 
mutation was not present in the parents and in family N3 the mutation could not be found in a 
healthy sister carrying the affected haplotype. This indicates a low mutation frequency, also 
shown by the rare finding of silent mutations in the coding sequence of PTEN in the normal 
population.
The identification of in vivo PTEN substrates might reveal the cellular signaling pathways 
that are normally regulated by PTEN. This strategy might also identify protein kinases that 
counteract the effects of PTEN and are thus potentially oncogenic. A good candidate for such
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a kinase is the recently identified LKB1 gene, a serine threonine kinase, which is involved in
42Peutz-Jeghers syndrome . Patients are predisposed to the formation of intestinal 
hamartomatous polyps, mucocutaneous pigmentation affecting lips, buccal mucosa and digits 
and to many different types of cancer. It remains to be seen if both these tumor susceptibility 
genes function in the same pathways.
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Abstract
Two hamartoma syndromes have been attributed to germline mutations in the tumour 
suppressor gene PTEN, Cowden Disease (CD) and Banayan-Riley-Ruvalcaba syndrome 
(BRR). Furthermore, a large number of somatic PTEN mutations have been detected in a wide 
variety of human cancers. The PTEN gene encodes a lipid phosphatase, which regulates 
phosphatidylinositol-3,4,5-triphosphate levels, and this activity is predicted to be disrupted by 
most of the identified mutations.
PTEN mutations have been found in CD and BRR suggesting that both phenotypes belong 
to a single genetic entity. The variety of clinical signs present in CD/BRR patients makes it 
plausible that patients with a “Cowden-like” phenotype might have PTEN mutations. To test 
this, we evaluated the clinical data and the results of PTEN sequence analysis of 23 patients 
offered for genetic testing of the PTEN gene.
Of the 23 patients analysed, five fulfilled the diagnostic criteria of CD if clinical data of the 
family were included. By sequence analysis of the entire PTEN coding sequence and the 
intron/exon boundaries we identified three germline mutations: a 253+1g^t splice site 
mutation in a familial CD patient, a 202 t^c  mutation in a combined CD/BRR family and in a 
BRR patient a 389g^a mutation. In 20 Cowden-like patients with symptoms often seen in 
CD, we did not find PTEN mutations. The data indicate that both macrocephaly and a 
combination of CD symptoms are not indicative for the presence of PTEN germline 
mutations. Based on these and earlier findings we conclude that PTEN germline mutations are 
likely to be confined to a CD/BRR phenotype. In addition, our data suggest that the CD 
diagnostic criteria are valid but emphasis on the dermatological criteria is in place.
Introduction
The tumor suppressor gene PTEN, also known as MMAC1, encodes a protein of 403 amino 
acids sharing homology with the active site of the dual specificity phosphatases (Li et al. 
1997; Steck et al. 1997). Recent experimental data show that the PTEN protein functions as a 
lipid phosphatase. PTEN dephosphorylates the 3’ position of phosphatidylinositol-3,4,5- 
triphosphate (PIP3), a product of phosphatidyl inositol 3-kinase (PI3K) (Maehama and Dixon 
1998). PTEN thus functions as an antagonist of PI3K. Loss of PTEN results in an 
accumulation of PIP3, which in turn allows hyper activation of PKB/Akt, a well-known anti- 
apoptotic factor. Activated PKB/Akt promotes cell survival by phosphorylation and 
inactivation of several death promoting target proteins (reviewed in (Vazquez and Sellers
- 7B -
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2000)). In addition to a role in the regulation of apoptosis, PTEN seems to have a role in cell 
migration through direct dephosphorylation of the focal adhesion kinase (FAK) and Shc (Gu 
et al. 1999; Tamura et al. 1998), and in growth control (Cheney et al. 1999; Furnari et al. 
1998).
The first PTEN germline mutations were reported in the inherited hamartomatous 
phenotype Cowden disease (CD; MIM 158350) (Liaw et al. 1997; Nelen et al. 1997). 
Characteristic features of CD include the multiple facial trichilemmomas, mucocutaneous 
lesions (e.g. oral papillomatosis), and the presence of hamartomatous outgrowths primarily in 
the skin, the breast, the thyroid and the gastrointestinal tract (Loyd and Dennis 1963; Starink 
et al. 1986; Weary et al. 1972). Prominent neurological features are macrocephaly and a 
dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease), which might be 
considered as a hamartomatous outgrowth in the cerebellum. (Lhermitte and Duclos 1920; 
Padberg et al. 1991; Starink et al. 1986). In addition, CD patients have an increased risk to 
develop various malignancies, of which breast and thyroid cancers are the most frequent 
(Longy and Lacombe 1996; Schrager et al. 1998). Germline mutations are also associated 
with Bannayan-Riley-Ruvalcaba syndrome (BRR; MIM 153480) and recent data suggest that 
CD and BRR are phenotypic variants of the same entity. Identical mutations have been found 
in both CD and BRR patients. Moreover, families have been described in which both 
syndromes are identified. (Marsh et al. 1999). The differences in phenotype might be 
explained by differences in genetic background.
The clinical phenotype associated with CD/BRR might represent only part of the 
phenotype caused by germline mutations in PTEN. However, several studies have excluded 
an important contribution of PTEN mutations in both familial and sporadic breast cancer, 
despite the increased frequencies of breast cancer in female CD patients (up to 75%) which is 
one of the major criteria of CD (Chen et al. 1998; FitzGerald et al. 1998; Freihoff et al. 1999; 
Shugart et al. 1999; Ueda et al. 1998). Furthermore, families with a combination of neoplasms 
of the breast and the thyroid or the brain show little or no involvement of PTEN (Lauge et al. 
1999; Marsh et al. 1998). Recently, rare PTEN germline mutations were identified in a 
population based study involving women with multiple cancers (de Vivo et al. 2000). To 
determine if other important clinical manifestations of CD might be more prevalent in a 
“Cowden-like” and PTEN associated phenotype, e.g. macrocephaly that is present in up to 
80% of CD patients (Starink et al. 1986), we evaluated the molecular genetic testing results 
and clinical data of patients for whom mutation analysis of the PTEN gene was requested. The 
majority of this group does not meet the CD diagnostic criteria (Nelen et al. 1996).
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Material and Methods 
Patients
Blood samples of 23 unrelated CD, BRR, and Cowden-like patients were offered for PTEN 
mutation analysis to the DNA diagnostic section of the UMC Nijmegen. All clinicians were 
asked to present clinical data of the proband and relatives (table1). Patients and families were 
evaluated for the criteria of CD as described previously (Nelen et al. 1996).
In brief, pathognomonic for the diagnosis of CD are facial trichilemmomas, acral keratoses 
and papillomatous, and mucosal lesions. Breast cancer, thyroid cancer, macrocephaly and 
LDD are considered to be major criteria. Thyroid lesions, mental retardation, hamartomatous 
gastrointestinal polyps, fybrocystic disease of the breast, lipomas, fibromas and genitourinary 
tumors or lesions are considered to be minor criteria. An individual is diagnosed with CD if 
there are mucocutanous lesions (six or more papules, of which at least three are 
trichilemmomas). Indicative criteria include: two major criteria, one of which is either 
macrocephaly or LDD; one major combined with three minor criteria; or four minor criteria.
Sequence Analysis
Genomic DNA of the patients was isolated from blood samples using a standard salt 
extraction procedure. PCR products of the 9 different PTEN exons were generated using 
intronic PCR primers (Steck et al. 1997) enabling sequence analysis of the exon/intron 
boundaries and the protein coding sequences. Cycle sequencing reactions were performed in a 
9600 Thermal Cycler (ABI) using the Big Dye terminator kit (ABI) according conditions 
recommended by the manufacturer. After precipitation samples were analyzed on an ABI 377 
automated sequencer.
Results
Clinical data of patients for whom PTEN mutation analysis was requested were evaluated 
for the criteria of CD as described by Nelen et al.(Nelen et al. 1996). One CD family (8075), 
one combined CD\BRR family (7890) and one BRR patient (8265) were typed on the basis of 
a positive clinical diagnosis. Twenty additional patients/families were typed because of the
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Table 1: Patients and their phenotype
Patient Birth Skin mucosa intestine thyroid Breast Neurological Remarks family diagnosis criteria
7Q97 m 1996 hemangioma pol. coli macrocephaly mother unaffected - 1 Ma / 2 Mi
71QB f 1922 uterine cancer family with breast ca. - 1 Mi + fam. ca.
osopharynx cancer brother prostate ca.
brain tumours
7174 f 1952 rectum carc-(44) cyst ductus sister (22) bilateral breast ca. - 1 Ma / 1 Mi
polyps thyroglossus niece breast ca.
7175 f 194S ptc benign cyst multiple lipomas aunt breast ca.(69) - 1 Ma/1 Mi + fam.
various types of cancer ca.
7SQ4 f 194B facial polyps fam. breast ca., colon ca., prostate ca., - 2 Mi + fam. ca.
neurofibromas pancreas ca.
7SQB f 195S fol. ca. (23) mastopathy, papillomatosis - 1 Ma + fam. Mi.
hyperthyroidism
7511 f 1921 basal cell carc. hyperthyroidism carc-(59) endometrium ca. (74) in fam. uterus extirpation, cystic - 1 Ma/2 Mi + fam
mastopathy, sister: breast, colon, vag. ca.
7óQ5 f 1951 facial papules breast ca. meningioma mastopathy
carc.
breastca, leukemia, l*hyperthyr - 2 Ma + fam. 1 Mi.
7BS4 f 1971 lesions hamartoma macrocephaly brother: hyperthyr., p-/fam + 1 Ma / 2Mi
father: macrocephaly
leukemia, breast ca., colon ca.
7B9Q * f 19ó1 thyroiditis macrocephaly son: diagnosed BRR sister: intestinal polyps p-/fam + lM a / lMi
mother breastca.
794Q m 19B4 macrocephaly, MR cal penis/back, - 1 Ma / 1 Mi
eczema
scoliose, vitiligo
7947 f 195Q multinod. goitre fam. anamnese breastca. - 1 Mi+fam. ca.
795S m 1976 juv. pol. 2 x  adenoma macrocephaly - 1 Ma / 2 Mi
BQ75 * f 19ó2 papillomatosis nodular macrocephaly diagnosed Cowden multiple family members affected +
B22S m 19S9 multiple macrocephaly, long body length - 1 Ma / 1 Mi
naevi/tumours ataxia prog. opticus atrophy
B2S1 m 199Q scr.tongue macrocephaly, MR parents unaffected - 1 Ma / 2 Mi
B265 * m ham. pol. macrocephaly, MR pigmented penis, +
diagnosed BRR
BS59 f 1954 fam. hyperthyroidism., thyroid adenoma - fam: 2 Mi-
BS62 f 1946 numerous thyroiditis uterus/adnex fam: breast ca., goitre, skin lesions p-/fam+ S Mi+fam. ca.
extirpation
papules mastopathy, nasal polyps
Bó4ó m 19ó1 scr.tongue macrocephaly lipomas son : macrocephaly, MR - 1 Ma / 2 Mi
B752 f 1946 benign nodule bilat. ca meningioma uterus extirpation unaffected - 1 Ma / 2 Mi
(46,5Q)
BBBQ f 1949 papillair ca.(40) a.o. colon ca., atheroma cysts - 1 Ma + fam. ca.
B971 m 19B4 possibly LDD - 1 Ma?
legend: bilat: bilateral; ca: cancer; cal: “cafe aux lait” ; carc: carcinoma; f: female; fam: family / familial; fol: follicular; ham. pol.: hamartomatous polyps; juv. pol.: juvenile 
polyps; m: male; Ma: major; Mi: minor; MR: mental retardation; p: patient; pol: polyps; pol. coli: polyposis coli; prog: progressive; scr: scrotal; (x): age; *: PTEN mutation
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presence of components of a CD phenotype or because of the presence of cancers that show a 
frequent involvement of PTEN. None of these patients fulfilled the CD criteria. When clinical 
data of the patient’s relatives were included, two families fulfilled the criteria
PTEN germline mutations were identified in three unrelated patients of the 23 patients 
screened (table 2). These mutations were not detected in 100 control alleles. Two mutations, 
located in exon 3 and exon 5, were missense mutations. The missense mutation 202 t^c  was 
identified in a female CD patient (7890) of a CD/BRR family. Her son, clinically diagnosed 
with BRR, was carrier of the same mutation. The detected mutation is predicted to result in 
the substitution of a histidine for a tyrosine residue (Y68H). The missense mutation 389g^a 
was identified in another BRR patient (8265). As a result, an arginine is predicted to be 
replaced by a glutamine (R130Q). A third mutation, identified in the familial CD patient 
8075, is predicted to affect splicing (253+1g^t). The screening of coding sequences and 
intron/exon boundaries in the PTEN gene failed to reveal germline mutations in the twenty 
additional patients (table 1). Intragenic microsatellite analysis indicated that no gross 
alterations were present in 25 % of these patients (data not shown).
Table 2: Description of the identified PTEN mutations and their predicted effect
Patient PTEN mutation Predicted effect
7B9Q 2Q2 T ^ C Y68H
BQ75 25S+1G^T Splice site mutation
B265 SB9 G ^ A R130Q
Nucleotide numbers are according to the genbank sequence U93051.
Discussion
DNA of twenty-three unrelated patients was screened for the presence of PTEN germline 
mutations using sequence analysis. Five patients fulfilled the CD diagnostic criteria if clinical 
data of the family were included (Nelen et al. 1996). Germline mutations were identified in 
three patients (13%). One patient (8075) had a 253+1g^t germline mutation likely to affect 
normal splicing and two patients had a missense mutation (Y68H and R130Q). The mutations 
have been reported previously and are predicted to affect PTEN lipid phosphatase activity 
(Marsh et al. 1998; Marsh et al. 1999; Nelen et al. 1999). All three patients with a PTEN 
mutation were diagnosed either with CD or BRR. In the two patients that only fulfilled the 
CD criteria when lesions present in the patient’s relatives were included we did not find PTEN 
mutations, which is also true for the eighteen patients with phenotypic components often
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present in CD. Gross deletions were excluded using an intragenic CA repeat polymorphism in 
25% of these patients. However, other types of PTEN inactivation mechanisms, such as 
promoter mutations or intron mutations creating an alternative splice site, cannot be ruled out. 
For the patients/families who fulfill the criteria for CD also genetic heterogeneity might 
explain the lack of a PTEN mutation (Tsou et al. 1997).
We and others have shown that up to 80% of the clinically well characterized CD patients 
have a PTEN germline mutation (Marsh et al. 1998; Nelen et al. 1999) and, likewise, up to 
60% of the BRR patients (Marsh et al. 1998). The overlapping clinical features of CD and 
BRR, their occurrence in a single family, and the fact that both share identical PTEN germline 
mutations indicate that they form a single entity (Marsh et al. 1999), and that phenotypic 
differences are likely due to differences in genetic background (modifier genes). This is 
underlined by the fact that the majority of the mutations detected in CD and BRR affect the 
lipid phosphatase activity of PTEN (Vazquez and Sellers 2000). So far, no mutations have 
been described that are clearly associated with a specific phenotype. However, a clear 
genotype-phenotype correlation in CD might be difficult to detect because of the large 
variation of expression among patients and even within families (Nelen et al. 1999). Because 
of this phenotypic variation we hypothesized the presence of PTEN mutations in patients 
presenting a ‘Cowden-like’ phenotype.
Overgrowth can be considered to be characteristic for CD, most often overgrowth of the 
brain. One of the first symptoms present in young CD patients is progressive macrocephaly 
(Hanssen and Fryns 1995) and a large number (up to 80%) of the adult CD patients show 
macrocephaly (Starink et al. 1986). Furthermore, increased size of hands, feet, and 
craniofacial bones can be found in a subset of CD patients. Interestingly, a young patient 
reported recently with both a germline and an early somatic PTEN mutation had, among other 
signs, a marked hemihypertrophy of the lower extremities(Zhou et al. 2000). Of the 23 
patients tested in the present study, macrocephaly was reported to be present in 10 patients 
(43%). The three mutations were detected in patients with macrocephaly. However, a PTEN 
mutation could not be detected in 70% of the patients presented with macrocephaly, 
indicating that macrocephaly on its own is a poor indicator of CD and the presence of PTEN 
mutations.
Increased risk to develop neoplasms is also a major characteristic of CD, particularly 
involving the skin, the breasts, the thyroid, and the intestine. Several combinations of tumors 
in these organs or tissues are present in this cohort of patients and/or families that do not 
fulfill the CD criteria. The fact that PTEN mutations are not detected in these patients
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indicates that combinations of tumors frequently part of the CD symptoms are not indicative 
for the presence of PTEN mutations. However, a recent study among women with multiple 
cancers indicate that PTEN mutations might be a predisposing factor for the formation of 
multiple tumors, and thus a more frequent finding than expected within the general population 
(de Vivo et al. 2000). Two novel PTEN germline mutations (V119L and V158L) were 
identified in this study, not found in CD or BRR. The amino acid changes are generally 
considered to be “mild” mutations and indeed, although the phosphatase activity of these 
mutations was not determined, transfection experiments into PTEN deficient breast cancer 
cell lines detected a tumor suppressor activity intermediate between wild type PTEN and 
phosphatase inactive PTEN mutants. Although the authors cannot exclude a possible 
diagnosis of CD, it is an intriguing hypothesis that these germline mutations lead to a 
clinically distinct phenotype that is at the border of the CD/BRR phenotypic spectrum. 
However, there is one issue that needs to be addressed in this matter. One has to search for the 
loss / inactivation of the second PTEN allele in tumors of these patients, providing evidence 
of the actual involvement of PTEN in tumor formation in these patients. Furthermore, it is 
striking considering the frequencies of the V119L and theV158L mutations ( 5%), which no 
one identified these mutations previously in the many patients and controls that have been 
tested for mutation in the PTEN gene. Skin hamartomas, in particular the pathognomonic 
facial trichilemmomas, belong to the most common findings in CD. They have been reported 
in more than 95% of the CD patients (Longy and Lacombe 1996). This observation is 
confirmed by two larger mutation analysis reports (Marsh et al. 1999; Nelen et al. 1999) in 
which a total of 43 out of 45 CD patients (95%) show involvement of the skin. But, skin 
lesions were only reported in six cases of the present group of patients and none of the lesions 
had a pathological confirmation of being a trichilemmoma. The low detection rate of PTEN 
mutations in this group of patients indicates that the presence of the pathognomonic skin 
lesions needs to be emphasized as a major criterion of CD.
In summary, based on these and previous observations showing that PTEN mutations are 
extremely rare in familial breast cancer, breast cancer combined with thyroid cancer in a 
patient or a family and familial breast cancer combined with brain tumors (Chen et al. 1998; 
Lauge et al. 1999; Marsh et al. 1998; Shugart et al. 1999), we can conclude that PTEN 
germline mutations seem to be restricted to a confined CD/BRR phenotype. PTEN mutations 
have been reported in a few juvenile polyposis syndrome patients (Lynch et al. 1997; 
Olschwang et al. 1998; Tsuchiya et al. 1998), but it has been argued that these patients could 
very well be diagnosed as CD patients (Eng and Peacocke 1998). For diagnostic molecular
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testing of the PTEN gene we conclude that a combination of CD components is not indicative 
for the presence of PTEN mutations if characteristic skin lesions, confirmed by pathological 
examination, are not present. Likewise, macrocephaly as a major criterion needs to be 
accompanied by typical skin lesions. It should therefore be used with caution as a major 
criterion, particularly in sporadic patients. In light of these findings we conclude that criteria 
as set out by the Cowden consortium are effective but special emphasis on the dermatological 
criteria is in place.
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PTEN mutation analysis in two genetic 
subtypes of high-grade oligodendroglial 
tumors: PTEN is only occasionally mutated in 
one of the two genetic subtypes
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Abstract
We recently identified two genetic subtypes of high-grade oligodendroglial tumors (HG- 
OTs): -1p/-19q HG-OTs are characterized by a loss of chromosome 1p32-36 (-1p32-36) 
and/or a -19q13.3 whereas +7/-10 HG-OTs harbor a gain of chromosome 7 (+7) and/or a -10 
without a loss of 1p32-36 and 19q13.3. Because a -10 and a +7 are most frequently detected 
in glioblastomas (GBMs), the genotype of +7/-10 HG-OTs suggests that these tumors are 
GBMs with a prominent oligodendroglial phenotype rather than anaplastic oligodendro­
gliomas. PTEN is a tumor suppressor gene, located at 10q23.3, which is involved in tumor 
progression of GBMs and other neoplasms. In this study we screened for PTEN mutations in 
six low-grade oligodendroglial tumors (LG-OTs), five -1p/-19q HG-OTs, seven +7/-10 HG- 
OTs, and nine xenografted GBMs. PTEN mutations were detected in none of the LG-OTs and - 
1p/-19q HG-OTs, once in +7/-10 HG-OTs, and frequently in GBMs. As one of the +7/-10 HG- 
OTs harbored a PTEN mutation this demonstrates that PTEN can be involved in the 
oncogenesis of this genetic subtype of HG-OTs. The lower frequency of PTEN mutations in 
+7/-10 HG-OTs compared to GBMs suggests that these tumors are of a distinct tumor type 
rather than GBMs.
Introduction
Oligodendroglial tumors (OTs) account for 5% to 33% of all gliomas [1, 2]. Allelic 
deletions on the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q) 
are detected in the majority of OTs [3, 4]. Recently, CGH analysis of pure OTs revealed two 
genetic subtypes within the histopathological phenotype of high-grade OTs (HG-OTs) 
without a prominent astrocytic component: -1p/-19q HG-OTs and +7/-10 HG-OTs [5]. The - 
1p/-19q HG-OTs are characterized by a loss of 1p32-36 and/or a loss of 19q13.3, genetic 
aberrations which were also present in all low-grade oligodendroglial tumors (LG-OTs) 
investigated by CGH [5]. The +7/-10 HG-OTs contain a gain of 7 and/or a loss of 10 without 
a loss of 1p32-36 or 19q13.3 [5]. The differences in the group of HG-OTs might be the result 
of the problem of clearly distinguishing these tumors on the basis of histological examination 
[5]. Because a loss of chromosome 10 and a gain of chromosome 7 are most frequently 
detected in the most malignant type of glioma, glioblastomas (GBMs) [6-8], the genotype of 
+7/-10 HG-OTs might suggest that these tumors are GBMs with a prominent oligodendroglial 
phenotype rather than anaplastic oligodendrogliomas.
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The tumor suppressor gene PTEN [9] or MMAC1 [1Q] which is located at lQq2S.S, 
belongs to the most commonly mutated genes in human cancer. Also, in a number of different 
types of tumors including melanomas and prostate cancer, PTEN is reported to be involved in 
tumor progression [11-13]. Germ-line mutations of the PTEN gene have been associated with 
Cowden disease and with two other distinct but related syndromes, Bannayan-Riley- 
Ruvalcaba syndrome and juvenile polyposis syndrome predisposing to multiple hamartomas 
[14-1B]. The PTEN gene encodes a dual specificity phosphatase that has been demonstrated to 
function in the regulation of cell growth, apoptosis, cell migration and interactions with the 
extracellular matrix [19, 2Q]. There are strong indications that at least an important part of 
these roles of PTEN are exerted by negative regulation of the PIS’K/PKB/Akt signaling 
pathway via dephosphorylation of the second messenger phosphatidylinositol S,4,5- 
triphosphate [2Q, 21].
In gliomas, PTEN alterations are most frequently detected in GBMs and only occasionally 
in less malignant gliomas indicating that PTEN alterations occur as a late event also in glioma 
oncogenesis [11, 22-25]. Although PTEN mutation analysis has been performed on more than 
BQQ gliomas, most frequently GBMs, HG-OTs were included only occasionally (5 or less HG- 
OTs per study [11, 25, 26]) and no distinction was made between the different genetic 
subtypes [9-11, 22-29]. The combination of a loss of chromosome 1Q and PTEN mutations in 
GBMs raises the question whether PTEN is also involved in the oncogenesis of +7/-1Q HG- 
OTs in contrast to -lp /-l9 q  HG-OTs. Similarities or differences in the incidence of PTEN 
alterations in +7/-1Q HG-OTs and GBMs might provide a better insight in whether +7/-1Q 
HG-OTs might be GBMs rather than anaplastic oligodendroglial tumors. The present study is 
designed to evaluate the involvement of PTEN in OTs, in particular in the two genetic subtypes 
of HG-OTs, and make a comparison with GBMs. We analyzed six LG-OTs, five -lp/-l9q HG- 
OTs, seven +7/-1Q HG-OTs, and nine xenografted GBMs for PTEN aberrations using SSCP 
analysis and sequencing. These tumors were previously screened for a loss of chromosome 1Q 
by comparative genomic hybridization (CGH) [5, B].
Materials And Methods 
Tumor Material
GBMs were obtained from xenografted tissue as described by Bernsen et al. [SQ]. OTs were 
obtained from surgical specimens. After surgery tumors were snap frozen in liquid nitrogen and
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stored at -80°C. Tumors were histologically classified and graded according to the WHO 
classification system [31]. Three independent neuro-pathologists classified the investigated 
malignant tumors as high-grade oligodendroglial tumors instead of GBMs [5]. As we only 
analyzed pure oligodendrogliomas, the tumors contained less than 5% astrocytic features 
indicating that the HG-OTs are definitely not ordinary GBMs [5]. Using CGH analysis, the 
tumors were genetically subtyped as -1p/-19q (tumors with a loss of 1p32-36 and/or 19q13.3) or 
+7/-10 (tumors with a gain of 7 and/or a loss of 10 and without a loss of 1p32-36 and 19q13.3) 
as described by Jeuken et al. [5]. Tumor characteristics are summarized in table 1.
DNA Isolation
Tumor DNA was extracted from frozen tissue and reference DNA was extracted from 
peripheral blood lymphocytes by a salting out procedure [5] modified from Miller et al. [32].
Mutation Analysis
Mutation analysis of the PTEN gene was performed as described by Nelen et al. [33]. 
Briefly, for SSCP analysis DNA fragments containing the exons of the PTEN gene were
32amplified using the primers described by Steck et al. [34]. [a- P]dCTP was incorporated and 
the PCR products were denatured and separated on a non denaturing 5% polyacrylamide gel 
containing 11.5% glycerol at 7 Watt at room temperature and 4°C. PCR products were 
visualized by autoradiography. Sequence analysis was performed using the same primers. 
Exons of the PTEN gene were amplified and purified using spin columns (Boehringer). 
Sequence analysis was performed on an ABI 377 automated sequencer using the ABI dye 
terminators rhodamine sequencing kit. Southern blotting was performed to detect homozygous 
deletions. Control DNA and tumor DNA were digested with PstI, blotted and hybridized with a 
full length PTEN cDNA probe. As a control probe PMP22 cDNA was used which is located at 
chromosome 17. The numbers of nucleotides and codons of the PTEN cDNA are according to 
Wang et al [22].
Results
The results of CGH analysis on OTs and xenografted GBMs will be reported in more detail 
elsewhere [5, 8]. Loss of a complete chromosome 10 was detected in none of the LG-OTs or -
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1p/-19q HG-OTs, in six out of seven +7/-10 HG-OTs, and in eight out of nine GBMs (Table 1). 
GBM E102 was the only tumor with a partial loss of chromosome 10 in which the PTEN region 
(10q23.3) was not included. In one GBM (E168) and in one +7/-10 HG-OT (T9) no loss of 
chromosome 10 was detected. Interestingly, the heterozygous constitution of a commonly 
detected polymorphism in intron 8 [22, 25, 35] confirmed the presence of both PTEN alleles in 
T9 and E102.
Table 1: Summary of tumor characteristics and PTEN mutation analysis
Tumor Malignancy grade Genetic subtype a Loss of #10 b
PTEN mutation analysis c: (exon, 












N184 HG-OT +7/-10 -10
N12 HG-OT +7/-10 -10 Ex 6 , 494G ^A , G165E
N40 HG-OT +7/-10 -10
T4 HG-OT +7/-10 -10
T5 HG-OT +7/-10 -10
T9 HG-OT +7/-10 ^
T13 HG-OT +7/-10 -10
E18 GBM +7/-10 -10
E49 GBM +7/-10 -10 Ex 8, 955insT, T319fs^324X
E80 GBM +7/-10 -10 Ex 6, 517C ^T , R173C
E98 GBM +7/-10 del(10)(q22-qter) Homozygeous deletiond
E102 GBM +7/-10 del(10)(pter-q21)
E106 GBM +7/-10 -10
E110 GBM +7/-10 -10 Homozygeous deletion
E120 GBM +7/-10 -10
E168 GBM +7/-10 Ex 5, 303dupl226-303 , 102fs^111X
a Using CGH analysis, the tumors were genetically subtyped as either -1p/-19q (tumors with a 
loss of 1p32-36 and/or 19q13.3) or +7/-10 (tumors with a gain of 7 and/or a loss of 10 without 
a loss of 1p32-36 and 19q13.3) as described by Jeuken et al. [5] 
b Loss of chromosome 10 as detected by CGH [5]
c The numbers of nucleotides and codons of the PTEN cDNA are according to Wang et al [22] 
d The deletion could not be confirmed by southern blotting
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All 9 exons of the PTEN gene were screened by SSCP analysis and/or sequencing. Since 
SSCP analysis does not detect all mutations [36], we sequenced exon 5, the most frequently 
mutated exon encoding the active site of the phosphatase [25, 37]. No additional mutations were 
found. SSCP analysis showed an aberrant migration pattern during gelelectrophoresis of exon 5 
in E168 (GBM), exon 6 in E80 (GBM), exon 6 in N12 (HG-OT), and exon 8 in E49 (Fig. 1). 
Sequence analysis of these exons revealed two missense mutations (N12 and E80), an insertion 
(E49), and a duplication of 38 nucleotides (E168). No aberrations were detected in the control 
DNAs. The mutations and their predicted effects are summarized in table 1. Although CGH 
detected no loss on chromosome 10 in E168, sequencing showed no heterozygosity. This 
suggests that the duplication, nt303(ins nt226-303), is either present in both PTEN alleles or that 
one of the chromosomes harbors a deletion including the PTEN allele which is too small to be 
detected by CGH. Since the detection limit for deletions by CGH is about 10 Mb [38] the latter 
explanation is the most plausible. Unfortunately this could not be confirmed by micro-satellite 
analysis because normal DNA was not available.
SSCP analysis on E98 (GBM) and E110 (GBM) showed no signal for part of the exons, 
indicating the presence of a homozygous deletion. DNA quality was checked by a positive PCR 
experiment. Southern blot analysis of E110 and control DNA using a PTEN cDNA probe 
revealed that 3 fragments were clearly absent in E110 (Fig. 2) confirming the presence of a 
homozygous deletion. The fragments detected by southern blot hybridization originate from 
remaining parts of the PTEN gene and from the PTEN pseudogene located at 9p21 [39]. 
Southern blot analysis of E98 was not successful due to the small amount of DNA available. 
However, this tumor is likely to contain a homozygous deletion of PTEN since the results of 
SSCP analysis are comparable to those of E110. SSCP analysis of the oligodendroglial tumors 
gave no indications for the presence of homozygous deletions.
Figure 1: SSCP analysis of PTEN exons. 
Sections from autoradiographs of SSCP gels 
showing control DNA (left) and tumor DNA 
(right). PTEN aberrations were detected in exon 
5 of tumor E168, exon 6 of tumor E80 and tumor 
N12, and in exon 8 of tumor E49
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Figure 2: Southern blot analysis of E110. Genomic DNA digested with Pst1 and 
was probed with a full length PTEN cDNA. Three fragments are clearly absent in 
E110. Intensity differences reflect the difference in DNA amount between both 
samples.
Discussion
We studied the involvement of PTEN in oligodendroglial tumors, especially in the two 
different genetic subtypes of HG-OTs, -1p/-19q HG-OTs and +7/-10 HG-OTs. By comparing 
the incidence of PTEN mutation analysis in +7/-10 HG-OTs and GBMs, we elucidated 
whether +7/-10 HG-OTs are GBMs rather than anaplastic oligodendrogliomas, as suggested 
by their genotype.
We, and others [11, 23, 25], did not detect any PTEN alterations in LG-OTs suggesting that 
the occurrence of PTEN mutations in glioma oncogenesis is a late event [11, 22-24]. The 
presence of PTEN mutations in the LG-OTs as detected by Duerr et al. [24] might be 
considered as an early marker for malignant progression. In contrast to -1p/-19q HG-OTs, in 
which loss of chromosome 10 and PTEN mutations were not detected, a loss of chromosome 
10q23 was detected in 88% (7/8) of the +7/-10 HG-OTs whereas a PTEN mutation was 
detected in only one of the +7/-10 HG-OTs tumors (1/8,14%). Although the number of 
tumors analyzed is small and homozygous deletions of the PTEN gene in tumor biopsies 
might be underestimated due to the presence of normal DNA, these results suggest that PTEN 
is not involved in the oncogenesis of -1p/-19q HG-OTs and only occasionally in the 
oncogenesis of +7/-10 HG-OTs. Previous reports did not describe PTEN mutations in HG- 
OTs [11, 25, 26]. However, it was not reported whether these tumors harbored -1p, -19q, - 
10q or +7, they might have been mainly -1p/-19q HG-OTs. In addition, the number of HG- 
OTs analyzed in these studies was small.
In accordance with previous reports [9-11, 22, 24-28], we detected a loss of 10q23 in seven 
GBMs (78%) and PTEN alterations in five GBMs (55%). This confirms our previous findings 
that GBM xenograft lines, from a genetic point of view, are valid models to study GBMs [8].
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Although the incidence of a loss of 10q23 in +7/-10 HG-OTs (6/7) and GBMs (7/9) is 
comparable, PTEN alterations were detected frequently in the GBMs (5/9) and only 
occasionally in +7/-10 HG-OTs (1/7). This suggests that these +7/-10 HG-OTs are not 
ordinary GBMs but represent a distinct tumor type. This is supported by the previous 
observation that patients with a +7/-10 HG-OT show a tendency towards longer post­
operative survival than patients with a GBM [5]. A larger sample number is necessary to 
further substantiate our observations, however the incidence of HG-OTs is low and high 
molecular weight DNA should be available to establish the genetic subtype using CGH.
Overall, six PTEN aberrations were detected in 27 gliomas: two missense mutations (N12 
and E80), a duplication (E168), an insertion (E49) and two homozygous deletions (E98 and 
E110). Both missense mutations (R173C and G165E) were detected in one of the three 
clusters with a high mutation frequency [37, 40]. This cluster is located at the beginning of 
exon 6 and encodes a highly conserved a-helix which is required for PTEN activity [37, 40], 
indicting that both missense mutations are likely to result in loss of PTEN activity by 
disturbance of this a-helix motif. The R173C mutation in E80 has been previously detected in 
GBMs [11, 24, 27, 41] whereas the G165E mutation in N12 has been detected previously in a 
patient with Cowden disease [33]. Another mutation in codon 165, G165R, has been reported in 
GBMs [22, 28, 29] and was shown to result in loss of PTEN activity [37]. The duplication in 
exon 5 of E168 is also predicted to cause a loss of phosphatase activity due to a premature 
stop of the protein at amino acid 111. This truncated protein does not contain the catalytic 
site which is located at amino acids 123-130 [10, 37, 40]. The T319fs^324X mutation in E49 
is new in GBMs and is predicted to result in a truncated protein missing one of the three 
potential tyrosine phosphorylation (residue 240, 315, and 336), both potential serine 
phosphorylation sites (residue 338 and 355), and the putative PDZ binding domain (the last 
four COOH-terminal amino acids) [42]. The latter was shown to be required for full growth 
suppression [43]. In E110 and E98 PTEN activity is lost due to a homozygous deletion.
The observation that loss of 10q occurs in a higher frequency than PTEN alterations 
indicates that other genes on this chromosome are involved in glioma oncogenesis. A 
candidate gene to be considered is DMBT1 which was recently identified from chromosome 
10q25.3-26.1 [44]. Loss of the DMBT1 locus was detected in both high and low grade 
gliomas indicating that this gene is involved early in the oncogenesis of gliomas [23, 45, 46]. 




In summary, in accordance with previous reports, PTEN aberrations were detected in none of 
the LG-OTs, occasionally in HG-OTs and frequently in GBMs indicating that PTEN is 
involved as a late event in glioma oncogenesis. One PTEN mutation was detected in a +7/-1Q 
HG-OTs which suggests that PTEN is occasionally involved in the oncogenesis of this genetic 
subtype of HG-OTs. The genotype of +7/-1Q HG-OTs suggests that these tumors are GBMs 
rather than pure anaplastic oligodendrogliomas. However, the observation that PTEN is only 
occasionally involved in +7/-1Q HG-OTs (14%) and frequently in GBMs (55%) supports the 
hypothesis that these +7/-1Q HG-OTs are not just ordinary GBMs but represent a distinct tumor 
type. This is supported by the previous finding that +7/-1Q HG-OTs show a tendency for 
longer post-operative survival than GBMs [5].
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Abstract
The PTEN gene is one of the most commonly mutated tumor suppressor genes in human 
cancer. Germline mutations in the PTEN gene cause Cowden disease (CD) and an increased 
risk to develop multiple neoplasms. Of the Dutch CD patients 80% show macrocephaly, one 
of the main developmental defects of CD, indicating a role of PTEN in brain development. 
This role is also underlined by the early embryonic death of PTEN-deficient mice. To provide 
more insight into the developmental role of PTEN we have performed RNA in situ 
hybridization using PTEN cDNA as a probe on cryosections of mouse embryos and both fetal 
and postnatal brain. The PTEN gene is transcribed ubiquitously. Interestingly, several tissues 
symptomatic in CD such as the thyroid, the skin and the primordia of the follicles of the 
vibrissae, show high transcript levels together with the thymus and the dorsal root ganglia. 
The latter are not involved in CD. Furthermore, several epithelia e.g. of the tongue and the 
intestine display a strong signal. In the developing brain PTEN transcripts are abundant, 
giving additional support to the hypothesis of an important role of PTEN in brain 
development. Postnatal expression is high in the olfactory bulb, the cerebral cortex and in the 
cerebellum. The expression is most prominent in the hippocampus. PTEN protein expression 
profiles during human development are compatible with the mouse data of the PTEN RNA in 
situ hybridization, suggesting that the PTEN knockout mice are good animal models to study 
the versatile role of PTEN during development in growth, differentiation and/or apoptosis
Introduction
The tumor suppressor gene PTEN, also called MMAC1, encodes a protein belonging to the 
family of dual specificity phosphatases and is involved in a wide variety of tumors1,2. The 
gene is one of the most commonly mutated tumor suppressor genes in human cancer. In some 
specific tumor types, such as gliomas, the gene is involved in tumor progression3. PTEN is a 
phosphatase that can use highly acidic tyrosine, serine and threonine peptides as a substrate in 
vitro4. More importantly, PTEN can dephosphorylate phosphatidyl-inositol (3,4,5)- 
triphosphate (PI(3,4,5)P3) at the D3 position of the inositol ring in vitro5-7 and an increasing 
amount of data indicate that this is also true in vivo5-9. Furthermore, experimental data show 
that the PI(3,4,5)P3 phosphatase activity is important for the tumor suppressor role of PTEN6. 
PI(3,4,5)P3, produced by the phosphoinositide 3-kinase (PI3K), is an important lipid second 
messenger and among others activates PKB/Akt that is a positive regulator of cell survival
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and growth10. Besides PI(3,4,5)P3, PTEN dephosphorylates focal adhesion kinase (FAK) and 
Shc in vitro, which suggests a role of PTEN in cell motility and adhesion11,12. Analysis of 
the crystal structure of PTEN revealed that PTEN has a C2 domain, a structure known to bind 
to the cell membrane. Moreover, structural analysis suggests an active role of this C2 domain 
in proper positioning of PTEN at the cell membrane13.
Germline mutations in PTEN cause Cowden disease (CD) (MIM 158350), a rare 
autosomal dominant familial cancer syndrome14,15 and Bannayan-Riley-Ruvalcaba 
syndrome (BRR)16,17. The occurrence of both CD and BRR in the same family suggests that 
these are phenotypes of a single entity18. Characteristic for CD are oral and facial papules, 
often accompanied by hamartomatous features of the thyroid, breast and digestive tract19-21. 
Pathognomonic for CD are multiple facial trichilemmomas. A dysplastic gangliocytoma, also 
known as Lhermitte-Duclos disease (LDD), that is found in some CD patients is considered to 
be a hamartoma of the cerebellum. It consists of hypertrophic ganglion cells in the cerebellar 
cortex in which normal Purkinje cells are often absent22. Also, CD patients have an increased 
risk of developing multiple neoplasms, frequently involving the thyroid and the digestive 
tract19,20. Female patients have a risk of up to 75% to develop breast cancer23. Besides an 
increased risk to develop benign and malignant neoplasms, patients with CD have 
developmental defects of which megalencephaly is the most common21. Overgrowth of 
hands, feet, cranial bones and breasts has also been described. Therefore, PTEN is very likely 
to have an important role in the development of different organs and tissues, which is 
underlined by the death of PTEN deficient mice before organogenesis 24-26, and the lethality 
in Drosophila at a late embryonic/early first instar larval stage27,28 in the absence of a 
functional PTEN gene. Heterozygous knockout mice show an increased tumor incidence but, 
in contrast to clinical signs present in CD, no developmental defects have been reported in
these mice 24-26.
We have performed RNA in situ hybridization (RISH) on PTEN transcripts during mouse 
embryogenesis and postnatal brain development to provide more insight into the function of 
PTEN during development and specifically the development of the brain. A detailed 
organo/histologic description of the ubiquitously expressed PTEN gene during different 
phases of mouse embryogenesis and postnatal brain development is given.
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Material and Methods
Tissue Preparation
Mouse embryos (E12.5, E14.5 and E16.5) and fetal brain (E18.5) were obtained from 
timed-pregnant C57BL/6 females crossed with C57BL/6 males derived from the central 
animal facility of the University Medical Center St. Radboud. Plug detection was considered
0.5-day post conception. Postnatal brains were obtained after birth at day P1, P4, P7, P10, 
P15 and from adult mice. Embryos and brain tissues were fixed in a 4% paraformaldehyde / 
PBS solution (overnight, 4°C) and transferred into 0,5M Sucrose / PBS solution (overnight, 
4°C). Subsequently, they were snap frozen in liquid nitrogen and stored at -70°C. 
Cryosections (10^m) were mounted on microscope slides and stored at -20°C until use.
RNA In Situ Hybridization (RISH)
A mouse cDNA clone encompassing the PTEN coding sequence, nt154-nt2198 (Acc.: 
U92437), cloned in pBluescript KS+ vector was used as a probe in RISH experiments. The 
probe was linearized, using KpnI or XbaI, to generate sense or anti-sense riboprobe, 
respectively. Probes were synthesized using T7 or T3 RNA polymerase (Promega Benelux
35B.V.) and a  S-UTP (400 Ci/mmol, Amersham). Alkaline hydrolysis reduced probe length to 
150-200 bp. Hybridization, washing, and RNAse treatment, were similar to Bachner et al29. 
Sections were coated with Ilford-K5 photo-emulsion and exposed (3-5 weeks). The slides 
were developed (D19, Kodak), fixed, and counterstained with Giemsa using standard 
protocols. Photographs were taken using a black and white film (Agfa-Ortho).
Results
We have investigated PTEN expression during mouse embryogenesis and postnatal 
development with special emphasis on brain using RISH techniques. In humans, the existence 
of a transcribed pseudogene, differing only in 18 nucleotides from the gene on chromosome
10, complicates RNA analysis30,31. However, Southern blot experiments using PCR products 
of human PTEN exon 6, 7, 8, and 9 separately as a probe on mouse genomic DNA, gave no 
indications for the presence of a PTEN pseudogene in mouse (data not shown). Thus, results
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of RISH on PTEN transcripts in mouse tissues will not be disturbed by a transcribed 
pseudogene. Cryosections of mouse embryos of E12.5, E14.5, and E16.5, and mouse brains of
35E18.5 and postnatal days 1, 4, 7, 10, 15 and adult were analyzed using an S-UTP labeled 
anti-sense PTEN riboprobe encompassing the entire protein coding sequence. Two 
independent experiments were performed.
Expression during prenatal development
The analysis of PTEN expression at day E12.5 to E16.5 during mouse development 
revealed that PTEN is ubiquitously expressed in tissues derived from all three germ layers. 
However, the level of expression differs between tissues and in general higher levels are seen 
in organs and tissues of ectodermal origin, including neural crest, and of endodermal origin in 
comparison to those of mesodermal origin. Very low levels of expression were only found in 
the developing heart and the primordia of the vertebrae, which are of mesodermal origin 
(table 1). At E12.5 (Fig. 1a and data not shown) a high expression is seen in the central 
nervous system, i.e. the brain and the spinal cord. In the brain the expression level is highest 
in the forebrain. The dorsal root ganglia of the developing peripheral nervous system exhibit 
the highest PTEN transcript level at this point of development. The thymus and the thyroid, 
both of endodermal origin, also exhibit a strong signal that is comparable to that of the dorsal 
root ganglia. The gut tube endoderm shows a somewhat elevated level of PTEN transcripts in 
comparison to the underlying layers. The accessory organs derived from the gut endoderm, 
the liver and the lung, display a high PTEN expression. This is also seen in the epithelium of 
the nasopharynx and the epithelium of the dorsum of the tongue. In the future nasal cavity 
high transcript levels are not only seen in the epithelium but in the underlying layers as well. 
Furthermore, the skin of the snout in the region in which the vibrissae develop shows a 
prominent expression. The skin covering the other parts of the body does not display a strong 
signal. Tissues derived from the gut endoderm that lack a high expression are the primordia of 
the pancreas. The mesodermal genital tubercle, mesonephroi (embryonic kidneys) and 
metanephroi (definitive kidney) show expression but not conspicuous and without 
differentiation of the signal within the organs.
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Table 1: a compilation of embryonic PTEN expression levels in the different organs / tissues 
and during postnatal brain development.
Embryonic expression of PTEN
dorsal root ganglia +++ mouth epithelium ++
trigeminal nerve ganglion +++ tongue epithelium ++
thymus +++ duodenum epithelium ++
vibrissae +++ midgut epithelium +
skin ++ liver +
brain ++ stomach +/-
olfactory epithelium ++ pancreas +/-
spinal cord ++ kidney +/-
tooth primordium ++ adrenal gland +/-
thyroid gland ++ urogenital +/-
vertebrae -
heart -
_______________________ PTEN expression in postnatal brain________________________
hippocampus +++ midbrain (th, hy) +/++
cortex ++ cerebellum +/++
olfactory bulb +/++ pons +
PTEN is ubiquitously expressed and already present at E12.5 but more pronounced at later 
stages (E14.5, E16.5 and postnatal brain). - : no or very low expression; + : expression; ++ : 
prominent expression; +++ : strong expression; th : thalamus; hy : hypothalamus
At E14.5 and E16.5 the expression pattern of PTEN is not markedly different from that at 
E12.5 still showing a ubiquitous expression. At E14.5 (Fig. 1b and data not shown) in the 
developing brain the strongest signal is found in the forebrain, like at E12.5. The ganglion of 
the trigeminal nerve (gasserian ganglion) shows a very high expression (not shown), as do the 
dorsal root ganglia. In the spinal cord the marginal layer with a very low signal can be 
discriminated from the mantle layer containing the neuronal cell bodies with a strong 
expression of PTEN. In the gut that showed a somewhat elevated signal at E12.5, a prominent 
signal can now, at E14.5, be seen in the mucosal lining of the duodenum and the further 
midgut (Fig. 1b, c). This lining begins to show evidence of differentiation. The epithelium of 
the stomach does not show a prominent expression. The signal in the epithelium is not 
stronger than that in the underlying part of the stomach wall. The primordia of the follicles of 
the vibrissae can be clearly recognized and start to penetrate the surface at E14.5. These 
primordia have a very strong PTEN expression in which a circular pattern can be recognized 
(Fig. 1e). The epidermis is discernable from the dermis and when signals were compared with
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bright field microscopy PTEN expression was found in both layers of which the dermis 
demonstrated the highest PTEN level. In the mandible the tooth germ can be recognized by a 
strong signal of PTEN RNA (Fig. 1b). The thymus (Fig. 1b) and the thyroid have a very 
prominent expression at E14.5 too. The expression in the dorsum of the tongue, lining of the 
mouth and the olfactory epithelium is lower than for example in the thymus but is prominent. 
The developing pancreas, urogenital sinus, metanephroi and adrenal glands have PTEN 
expression but not at a high level in comparison to other tissues. There is no differentiation in 
the expression pattern within these organs.
Figure 1: PTEN transcript levels in E12.5, E14.5 and E16.5 mouse embryos.
Dark-field illuminations of entire sagittal sections through a mouse embryo are shown of 
E12.5 (a) and E14.5 (b), bar represents 1 mm. Details are given of the small intestine at E14.5 
(c) and E16.5 (d), the primordia of the vibrissae at E14.5 (e) and the skin at E16.5 (f), bar 
represent 100 ^m. Hybridization with a control sense PTEN riboprobe, gave no signal above 
background levels, mouse embryo E12.5 (g). d, dermis; drg, dorsal root ganglia; e, epidermis; 
g, gut; he, heart; li, liver; lu, lung; oe, olfactory epithelium; pfv, primordia of follicles of 
vibrissea; sc, spinal cord; st.c, stratum corneum; t, tongue; th, thymus
- 105 -
Expression of PTEN in mouse during development
For E16.5 embryo’s (not shown), in comparison to those of E14.5, the high expression in 
the cortical plate is worthwhile to mention. Furthermore, there is a high expression in the 
submandibular gland and the brown adipose tissue in the neck region. In the midgut the 
increased degree of differentiation of the mucosa is apparent and the PTEN expression 
remains high (Fig. 1d). The rectum also shows an elevated signal in its epithelial lining in 
comparison to the surrounding tissues. The endodermal lining of the bladder shows an 
increased expression in comparison to the underlying muscular wall. In the skin there is a 
high expression in both the epidermis and the dermis. Using bright field microscopy, it 
appears that the strongest signal is located in and flanking the epidermal basal layer (Fig. 1f). 
Also in the normal (non-vibrissae) hair follicles PTEN is expressed.
Expression in late prenatal and early postnatal brain development
Macrocephaly is often the only symptom of CD present in young children, suggesting an 
important function of the PTEN gene in brain development19. We therefore decided to study 
PTEN expression in both fetal and postnatal mouse brain cryosections, using RISH. The 
PTEN gene is abundantly expressed throughout the different stages of brain development, 
both prenatally and postnatally (table 1, fig 2,3).
In the cerebellum, the signal is not homogeneous from E18.5 onward (Fig. 2). The external 
germinal layer and the Purkinje cell layer are discernable by a somewhat higher expression. 
The deep nuclei have the strongest signal (Fig. 2a, b). Later, at postnatal day 7 (Fig. 2c), the 
internal germinal layer consisting of the developing granular layer and Purkinje cells show a 
strong signal as well. The cerebellar molecular layer and white matter areas demonstrate low 
signal intensity. This pattern is present until the external germinal layer gradually becomes 
narrower and disappears (end of third week) (Fig. 2d-f). From P15 onward, the Purkinje cell 
layer is discernable from the cerebellar granular layer by a somewhat higher level of 
expression (Fig. 2e, f).
The olfactory bulb at E18.5 and postnatal day 1 (P1) expresses PTEN in all cell layers with 
the strongest signal in the mitral cell layer and a very weak signal in the external and internal 
plexiform cell layers (Fig. 3 a). Later, the level of expression in the glomerular and granular 
layers equals that of the mitral cell layer (Fig. 3b).
During the process of stratification in the wall of the telencephalic vesicles, at E18.5 a 
somewhat stronger signal can be seen in the cortical plate compared to the ventricular zone 
and the intermediate zone (Fig. 3c). The signal in the latter is the weakest. With further
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Figure 2: PTEN expression in the developing cerebellum.
Details of sagittal sections of mouse brains at E18.5 (a), p4 (b), p7 (c), p10 (d), p15 (e) and 
p20 (f) are given in dark-field illumination. Bars represent 100 ^m (a,b,c) or 200 ^m (d,e,f). 
Hybridization with a sense PTEN riboprobe, used as a control experiment, gave no signal 
above background levels. dn, deep nuclei; egl, external germinal layer; igl, internal granular 
layer; gl, granular cell layer; ml, molecular layer; p1, purkinje cell layer
differentiation from E18.5 onwards, no or a very weak signal is present in the outer marginal 
zone whereas a strong signal can be seen in the cortical plate. Expression levels in the 
intermediate zone are weak, but somewhat higher in the underlying ventricular zone. This 
pattern does not change during further maturation. The level of expression in the cerebral 
cortex is higher than the level in mid- and hindbrain. The highest transcript level is seen in the 
hippocampal granular cell layer of the dentate gyrus and the pyramidal neurons (CA1, 2, 3) of 
Ammon’s horn from P4 up to adult (Fig. 3 d, e).
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In the thalamus and in the ventromedial, the dorsal medial and the medial mammilary 
nuclei of the hypothalamus, an elevated PTEN expression is seen from E18.5 onward (Fig. 
3f). In the midbrain this holds true for the superior and inferior colliculus and in the pontine 
area of the brain stem for the pontine gray nucleus and the dorsal tegmental nucleus (Fig. 3f).
Figure 3: In situ hybridization of PTEN transcripts on sections of mouse brain.
Details of dark-field illumination of sagital sections are shown. (a) Olfactory bulb at E18.5 
and (b) p10. (c) Cerebral cortex at E18.5. (d) Developing hippocampus at p4 and (e) p7. (f) 
Entire section of the mouse brain at p1. Bars represent 100 ^m (a through e) and 1mm (f). 
Hybridization with a sense PTEN riboprobe, used as a control experiment, gave no signal 
above background levels. c, cerebellum; cc, cerebral cortex; cp, cortical plate; 
CA1,CA2,CA3, regions of Ammon’s horn; dg, dentate gyrus; epl, external plexiform layer; 
gcl, granular cell layer; gll, glomeral layer; hc, hippocampus; hy, hypothalamus; ipl, internal 





Somatic mutations in the human PTEN gene, encoding a member of the dual specificity 
phosphatase family, are linked to tumorigenesis in a large number of different tissues and 
germline mutations cause CD and BRR. Developmental defects in both CD and BRR, of 
which overgrowth of the brain is the most common one, point to an important role of PTEN in 
development and especially in brain morphogenesis. This is corroborated by an early 
developmental stop in mouse and Drosophila when a functional copy of the PTEN gene is 
absent24-28. To obtain clues on the developmental role of PTEN and to see if the mouse is a 
good model system to perform developmental studies we have examined the expression 
profile of PTEN using RISH during both fetal mouse and postnatal brain development.
Northern blot analysis had revealed that PTEN is expressed throughout mouse 
embryogenesis, PTEN mRNA can be detected as early as E7, and also in adult mouse and 
human tissues PTEN is widely expressed1,25,32. Our results show that PTEN is ubiquitously 
expressed during mouse development and that several tissues stand out. Highest levels are 
observed in e.g. multiple ganglia, in particular the dorsal root ganglia and the gasserian 
ganglion, the brain, the spinal cord, the thymus, the thyroid gland, the follicles of the 
vibrissae, the skin and the epithilia of the tongue and the intestine. Little change was observed 
in these expression levels during the different stages of development.
It is interesting to note that several of these highly expressing organs or cell layers are 
symptomatic in CD. Multiple facial trichilemmomas, benign tumor-like outgrowths of the 
outer root sheath of hair, and multiple hamartomas of the skin and mucous membranes such 
as oral papillomas and intestinal polyps are among the main characteristics in CD patients. 
The high expression levels detected in the follicles of the vibrissae, the skin, the thyroid, and 
the mucous lining of the gut in mice correlate very well with these CD symptoms. 
Furthermore, heterozygous knockout mice develop dysplastic lesions in the colon mucosa and 
the skin24. Interestingly, experimental data suggest that these lesions could be due to PTEN 
haplo-insufficiency, as mouse intestinal polyps seem to retain the normal PTEN allele24. This 
is in contrast with PTEN’s current status as a human tumor suppressor gene. Namely, loss of 
heterozygosity has been described in various tumors but also in hamartomatous tissues of CD 
patients such as fibroadenomas of the breast, a thyroid adenoma, and a lung hamartoma and 
also in a LDD lesion33,34(unpublished results).
Thymic lesions, although a prominent feature after radiation in heterozygous knockout 
mice25, are rarely found in CD patients. PTEN expression in the thymus is very high in the
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developing mouse and comparable results were shown during human development, 
confirming this contrast of high PTEN expression in the thymus and CD 35. A likely 
explanation is that most CD symptoms, also the hamartomas, usually develop in or after the 
second and third decade of life when the thymus is already degenerated. The high expression 
level in the dorsal root ganglia throughout development is also not reflected in symptoms of 
CD. Ganglioneuromas are rare as are other types of central nervous system lesions in CD, 
apart from LDD and megalencephaly. In line with this, there seems to be no elevated risk to 
develop neoplasms in the central nervous system in heterozygous knockout mice.
In the developing mouse brain, the cerebral cortex, the cerebellum and the olfactory bulb 
show higher transcript levels of PTEN in comparison to other regions of the brain. In part, this 
higher expression is attributed to the different granular layers present in these three structures. 
These layers have a high cell density that might result in the high level of PTEN expression. 
Relatively high PTEN expression was also noted in the developing human brain that 
continued in the normal human adult brain 35. This overall expression pattern in the brain 
agrees very well with symptoms present in CD patients. Overgrowth of the brain is detected 
in 80% of the Dutch CD patients and is most obvious in the cerebrum. Histological 
examination revealed no abnormalities36. Given that PTEN functions in the PI3K signaling 
pathway and absence of PTEN and/or activation of PKB/Akt results in a decreased apoptotic 
sensitivity detected in various cell types, including cerebellar neurons7,37,38, a likely 
explanation for the overgrowth might be an increase in the number of neurons and possibly 
glial cells. However, an increase in cell size might also be part of the cause of the brain 
overgrowth as in Drosophila the dS6 kinase, a down stream target of PKB/Akt, has been 
identified as a regulator of cell size39. Both the internal and external granular layers express 
PTEN during postnatal cerebellum development. Interestingly, a fraction of CD patients 
develop LDD, considered as a hamartomatous lesion consisting of hypertrophic ganglion cells 
in a disorganized granular layer of the cerebellar cortex. This points to additional functions of 
PTEN namely in regulating cell proliferation, differentiation and/or migration in the brain. 
Involvement of PTEN in cell migration is in line with earlier observations11,12,27 and in 
Drosophila a role of PTEN in cell growth has been demonstrated27,28.
Surprisingly, no developmental defects pointing to overgrowth such as macrocephaly have 
been detected in heterozygous PTEN deficient mice24-26. However, an argument in favor of 
the mouse being a good model for studying the role of PTEN in brain development is that 
levels of the insulin-like growth factor 1 (IGF-1), which indirectly activates PI3K, seem to
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correlate well with brain size affecting all brain areas40"42. Furthermore, both in 
Caenorhabditis elegans and Drosophila PTEN seem to function as a major regulator in the 
insulin-signaling pathway 27,28,43,44.
Recently, PTEN protein expression was studied during human development 35. This study 
confirmed the ubiquitous PTEN expression identified in previous studies. Also this study 
noted a more pronounced PTEN expression during the later stages of development. Murine 
and human PTEN expression shows remarkable similarities with high PTEN expression in 
e.g. skin, thyroid and the central nervous system. Also in human several tissues were 
identified as high PTEN expressing tissues that are rarely involved in PTEN related 
syndromes, e.g. the thymus and the peripheral nerves. These results are also in favor of PTEN 
deficient mice being useful models to study the diverse role of PTEN.
Overall, the expression data in mouse correlate well with the symptoms seen in CD, 
although several tissues considered not to be at risk in humans express PTEN at a relatively 
high level in the mouse. The expression pattern of PTEN in mouse development is in line 
with a general role of PTEN in growth control of multiple cell types. The pattern also fits a 
versatile role of PTEN in developmental processes of apoptosis, differentiation and/or cell 
migration. Tissue- and stage-specific disruption of PTEN is necessary to obtain more detailed 
information on specific functions of PTEN in the development of different organs and tissues.
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Summary
The study of families in which a rare “cancer gene” segregates has been of a tremendous 
value in the identification of “cancer genes” and also for our understanding of both inherited 
and sporadic forms of cancer. Cowden disease (CD) is such a familial cancer disorder, which 
is characterized by multiple hamartomas in various organ systems, including skin, thyroid, the 
breast, the central nervous system and the gastrointestinal tract. The hallmark hamartoma of 
CD is the facial trichilemmoma, a benign disorganized outgrowth of the hair follicle. CD 
patients have an increased risk of developing cancer, particularly breast and thyroid cancer. 
The gene(s) for CD display an autosomal dominant mode of inheritance.
Our objective was to identify the gene (or genes) involved in CD and to elucidate its role in 
tumorigenesis and brain development. The initial goal was to map the CD gene. Since 
cytogenetic analysis of CD patients did not provide any clues, linkage analysis was the next 
obvious molecular genetic tool. This approach required a genome wide scan with genetic 
markers in five Dutch CD families. Using this technique we were able to show that 
chromosomal region 10q22-23 cosegregated with the CD phenotype (appendix 1). We were 
able to pinpoint the CD gene to a 5 cM region between the markers D10S215 and D10S564 
with no indications for genetic heterogeneity. As we set out to reduce the critical region and to 
identify the CD gene involved, using positional cloning strategies and the candidate gene 
approach, three groups identified a gene mutated in multiple cancers. Two of these groups 
used a technique often referred to as loss of heterozygosity (LOH) to pinpoint the gene now 
known as PTEN. It contains an active site motif present in dual specificity phosphatases. The 
gene was located within the identified critical region and obviously an excellent CD candidate 
gene. Indeed, germline mutations were detected in CD patients and thus PTEN was identified 
as the gene involved in CD (appendix 2). It was the first phosphatase identified that behaves 
as a tumor suppressor gene and it provided the long expected link to growth control and 
tumorigenesis. Biochemical studies have shown PTEN activity for the 3’ position of Ptdlns- 
3,4,5-P3, a membrane-associated second messenger. Thereby, PTEN regulates a variety of 
signaling molecules of which PKB/Akt seems to be the most important. Approximately 80% 
of the CD patients have a germline mutation indicating that PTEN is the major gene involved 
in CD. However, in 20% of the CD patients no PTEN germline mutations are detected. This 




Two large studies tried to identify genotype-phenotype correlations but no obvious 
correlations were found. This is likely due to the variable expression of the disease, even 
within families (appendix 3). Germline PTEN mutations were also identified in a related 
hamartomatous syndrome, Bannayan-Riley-Ruvalcaba (BRR). PTEN-mutated families were 
identified in which both phenotypes were present, indicating that both phenotypes belonged to 
a single entity. Furthermore, the presence of modifier genes is a likely explanation for the 
variable spectrum of this single entity. The variation in the phenotypic expression of PTEN 
mutations led us to examine the range of the phenotype indicative for the presence of PTEN 
mutations. We evaluated the molecular genetic testing results and the clinical data of 23 
patients presenting a “Cowden-like” phenotype and concluded that it is likely that a PTEN- 
associated phenotype is limited to the CD/BRR phenotype (appendix 4).
Following the identification of the PTEN gene extensive mutation analysis of this gene was 
performed in somatic tumors. PTEN mutations have been described in a wide variety of 
cancers. In some cancers, such as glioblastomas and prostate cancer, PTEN mutations are 
associated with tumor progression while in others (endometrial cancers) PTEN loss appears to 
be an early event. We have studied two genetic subtypes of the oligodendroglial tumors (OT), 
of which one frequently shows (partial) loss of chromosome 10, and compared them with 
glioblastomas for the presence of PTEN mutations. PTEN mutations were not identified in 
low grade OT and only one mutation was detected in the high grade OT. In contrast, PTEN 
mutations are a frequent finding glioblastomas (GBM) suggesting that the high grade OT are 
a distinct tumor type rather than GBM (appendix 5). The combined data of the mutation 
analysis studies in cancer show that PTEN is one of the most common targets of mutation in 
human cancer.
Finally, to provide more insight in the developmental aspects of PTEN activity we have 
performed a detailed RNA expression analysis during embryogenesis and postnatal brain 
development in the mouse. The results confirmed the ubiquitous expression of PTEN as found 
with Northern blot analysis, although several tissues do stand out. The expression levels 
found in the follicles of the vibrissae, the skin and the mucous lining of the gut correlate well 
with CD symptoms. However, high expression levels are also found in tissues considered not 
to be at risk in humans. Overall, the general expression pattern fits the versatile role of PTEN 
in multiple cell types (appendix 6).
In conclusion, the characterization of the genetic defect in CD has provided the tools for 
reliable post- and prenatal diagnosis and has given us new insights in the process of 
oncogenic transformation (chapter 2).
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Samenvatting
Het bestuderen van families waarin een zeldzaam “kanker” gen segregeert is niet alleen 
van zeer groot belang geweest voor het vinden van deze “kanker”genen maar ook voor het 
inzicht dat we nu hebben in erfelijke en sporadische vormen van kanker. De familiaire aanleg 
voor kanker is ook aanwezig bij de ziekte van Cowden (CD), met name voor borst- en 
schildklierkanker. Karakteristiek voor dit ziektebeeld zijn de hamartomen die gevonden 
kunnen worden in verschillende organen en weefsels waaronder de huid, de schildklier, de 
borsten, het central zenuwstelsel en het maag-darm kanaal. Het specifieke symptoom voor dit 
ziektebeeld is de trichilemmoma in het gezicht, een goedaardige uitgroei van het haarzakje. 
Dit erfelijke ziektebeeld heeft een autosomaal dominante overerving.
Aan de start van het onderzoek hadden wij ons tot doel gesteld om het gen (de genen) te 
identificeren die betrokken is (zijn) bij CD en de rol die het speelt in tumorgenese en 
hersenontwikkeling. De eerste stap hiertoe was het vinden van de chromosomale lokalisatie 
van het CD gen. Eerdere onderzoeken, waaronder cytogenetische analyse, leverden niets op. 
Daarom werd besloten een koppelingsonderzoek te starten in 5 Nederlandse families. 
Gebruikmakend van deze strategie konden wij aantonen dat een gebied van chromosoom 10, 
q22-23, overerft met het CD fenotype (appendix 1). Het gebied van ongeveer 5cM werd 
gemarkeerd door de merkers D10S215 en D10S564. Er werden in deze studie geen 
aanwijzingen gevonden voor genetische heterogeniteit. De volgende stap was het verkleinen 
van het CD-gebied met behulp van positionele kloneringstechnieken en het testen van 
kandidaat-genen uit dit gebied. Drie andere groepen identificeerden echter een nieuw gen 
welke betrokken was bij verschillende soorten tumoren. Twee groepen maakten gebruik van 
het verlies van heterozygotie in tumoren om het PTEN-gen, zoals het nu genoemd wordt, te 
vinden. Het gen bevat een motief die gevonden wordt in de actieve site van “dual specificity” 
fosfatasen en was gevonden in het chromosomale gebied dat betrokken was bij CD en dus een 
duidelijk kandidaat-gen. Inderdaad werden er erfelijke mutaties gevonden in CD patiënten en 
hiermee werd aangetoond dat PTEN betrokken is bij CD (appendix 2). PTEN is het eerste 
fosfatase dat herkend is als een tumor suppressor gen en was hiermee het lang verwachte 
bewijs van de rol die fosfatasen spelen bij celgroei en tumorigenese. Biochemische studies 
hebben ondertussen aangetoond dat PTEN fosfatase activiteit specifiek is voor de 3’positie 
van het PtdINS-3,4,5-P3, een membraangekoppelde second messenger. PTEN reguleert 
hiermee de activiteit van verschillende signaaleiwitten waarvan op dit moment PKB/Akt de 
meest belangrijke lijkt. Ongeveer 80% van de CD patiënten heeft een mutatie in het PTEN
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gen. Echter, in 20% van de CD patiënten wordt geen PTEN mutatie gevonden. Deze patiënten 
hebben mogelijk een mutatie in een intron of de promotor van PTEN. Dit kan echter ook 
duiden op genetische heterogeniteit.
Twee grote studies hebben geprobeerd genotype-fenotype correlaties te vinden. De grote 
variatie in expressie van het ziektebeeld, zelfs binnen families, is waarschijnlijk de 
belangrijkste reden dat deze niet werden gevonden (appendix 3). Erfelijke PTEN mutaties 
werden ook gevonden in een gerelateerd ziektebeeld, nl. Banayan-Riley-Ruvalcaba (BRR). Er 
zijn ook families gevonden met PTEN mutaties waarin zowel CD als BRR gediagnostiseerd 
is. Het is dus waarschijnlijk dat beiden fenotypes tot hetzelfde ziektebeeld behoren. Een 
logische verklaring voor deze variatie in expressie is de invloed van “modificeer” genen. De 
verscheidenheid in expressie van PTEN mutaties is mogelijk nog breder. Om dit te bestuderen 
hebben we de resultaten van de PTEN mutatie analyse bij 23 Cowden-like patiënten 
gecombineerd met het klinisch beeld van de patiënten. De belangrijkste uitkomst van deze 
studie is dat het erg waarschijnlijk is dat het PTEN-fenotype beperkt is tot CD en BRR.
Een groot aantal verschillende somatische tumoren werden geanalyseerd op het al of niet 
aanwezig zijn van PTEN mutaties. En inderdaad werden er grote aantallen mutaties gevonden 
in deze tumoren. In sommige tumoren , zoals glioblastomas en prostaatkanker, zijn PTEN 
mutaties geassocieerd met tumorprogressie, terwijl in andere tumoren (bv. endometrium 
tumoren) verlies van PTEN-activiteit juist een vroege gebeurtenis in de tumorontwikkeling is. 
Wij hebben twee genetische subtypes van de oligodendrogliale tumoren (OT) bestudeerd, 
waarvan er 1 vaak een verlies van een (gedeelte)chromosoom 10 laat zien, en deze vergeleken 
met glioblastomas (GBM) op het hebben van PTEN mutaties. Mutaties werden niet gevonden 
in de laaggradige OT en maar één mutatie werd gevonden in de hooggradige OT. Echter, in 
GBM worden frequent mutaties gevonden en deze bevinding duidt erop dat hooggradige OT 
een herkenbaar subtype is en geen GBM (appendix 5). De grootschalige mutatie analyse van 
een groot aantal verschillende tumoren laat zien dat PTEN tot een van de meest gemuteerde 
genen behoort in humane kanker.
Als laatste hebben we geprobeerd meer inzicht te krijgen in de ontwikkelingsaspecten van 
PTEN door een gedetailleerde analyse van het RNA-expressie patroon van PTEN tijdens de 
embryogenese en de postnatale hersenontwikkeling in de muis. De resultaten bevestigden de 
algemene expressie van PTEN, eerder gevonden m.b.v. Northern blot analyse. Er zijn echter 
een aantal weefsels/organen die opvallen door de hoge expressie die gevonden wordt. De 
verhoogde expressie in bv. de follikels van de vibrissae, de huid en het darmepitheel 
correleert met de verschijnselen die in CD gevonden worden. Er zijn echter ook weefsels die
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een hoge PTEN expressie hebben maar waaraan geen risico verbonden is bij de mens. De 
algemene expressie die gevonden wordt in de muis past bij de veelzijdige rol die PTEN speelt 
in verschillende celtypes.
Samenvattend, de identificatie en karakterisatie van het genetisch defect in CD heeft het 
mogelijk gemaakt om betrouwbare post- en prenatale diagnostiek toe te passen en heeft 
bijgedragen tot nieuwe inzichten in het proces van oncogene transformatie (hoofdstuk 2).
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